RGLS8429  
Protocol RGLS8429-[ADDRESS_592552] (IP)  RGLS8429 
PROTOCOL NUMBER:  RGLS8429-01 v3.0 PROTOCOL DATE:  6 June 2022 IND NUMBER:  158708 SPONSOR NAME / ADDRESS: 
   Regulus Therapeutics Inc. 
[ADDRESS_592553] San Diego, CA [ZIP_CODE] [LOCATION_002]  
 
  
CONFIDENTIAL 
This protocol is provided to you as an Inves tigator, potential Investigator, or consultant for 
review by [CONTACT_10825], your staff, and ethics commit tee/institutional review board. The information 
contained in this document is regarded as co nfidential and, except to the extent necessary 
to obtain informed consent, may not be disclose d to another party unless such disclosure is 
required by [CONTACT_27614]. Persons to whom the information is disclosed must be 
informed that the information is confidentia l and may not be further disclosed by [CONTACT_476]. 
  
RGLS8429  
Protocol RGLS8429-01 v3.0  Regul us Therapeutics Inc. 
Confidential and Proprietary 2 6 June 2022 DOCUMENT HISTORY 
Version Version Date Summary of Changes and Rationale 
Version 1.0 9 March 2022 Not Applicable 
Version 2.0 09 May 2022 The prot ocol is being amended to: 
1. NCI CTCAE Version 5.0 scale to 
rate adverse event severity in this 
healthy volunteer study, is replaced with the Guidance for Industry: 
Toxicity Grading Scale for Healthy 
Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 
Clinical Trials (September 2007)  for 
all the parameters except for serum creatinine.  The KDIGO Clinical 
Practice Guideline for Acute Kidney 
Injury (https://kdigo.org/wp-content/uploads/2016/10/KDIGO-
2012-AKI-Guideline-English.pdf) 
will be used to rate serum creatinine adverse event severity. Add AKI 
criteria to Section 3.2, Dose 
Escalation and Stoppi[INVESTIGATOR_1869].  
2. Increase the sampling window for 
the collection of post-dose 
pharmacokinetic plasma samples when multiple procedures are being 
performed at the same nominal 
timepoints.   
3. Clarify that the NuvaRing is an 
acceptable depot contraceptive. 
4. Allow the pre-dose ECG tracing to 
be obtained and the SARA test to be 
performed, prior to the start of 
Holter monitoring at the 60 minute pre-dose timepoint on Day 1. 
Version 3.0 6 June 2022 The prot ocol is being amended to: 
1. Change the RGLS8429 dose for 
FRKRUWIURPÂ”  5.0 mg/kg to 
4.0 mg/kg. The dose of 4mg/kg has been selected for cohort [ADDRESS_592554] reviewed this protocol and find its cont ent to be acceptable.  

RGLS8429  
Protocol RGLS8429-01 v3.0  Regul us Therapeutics Inc. 
Confidential and Proprietary 5 6 June 2022 SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_462800]: _______________________________________ 
By [CONTACT_27616], I agree to personally supervise the conduct of this study at  my study site and to 
ensure its conduct is in compliance with the protoc ol, informed consent, In stitutional Review Board 
(IRB)/Ethics Committee (EC) procedures, instru ctions from Regulus representatives, the 
Declaration of Helsinki, Intern ational Conference on Ha rmonisation (ICH) Good Clinical Practices 
Guidelines, and local regulations governi ng the conduct of c linical studies. 
 
RGLS8429  
Protocol RGLS8429-01 v3.0  Regul us Therapeutics Inc. 
Confidential and Proprietary 6 6 June 2022 PROTOCOL SYNOPSIS 
Study Title:  
A Phase 1, Double-Blind, Placebo-Controlle d, Single Ascending Dose Study in Healthy 
Volunteers to Evaluate the Safety, Tolera bility, and Pharmacokinetics of RGLS8429 
Protocol Number: RGLS8429-01 (IND 158708) 
Indication: Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
Study Type: Phase 1, dose range-ranging study in healthy volunteers 
Study Population: Approximately 32 healthy volunteers  
Study Sites:  Phase 1 Clinical Research Unit in the [LOCATION_003] 
Sponsor: Regulus Therapeutics Inc. 
Study Drugs:  
RGLS8429 injection will be provided in [ADDRESS_592555] the labeled volume of 1 mL of 150mg/mL of RGLS8429 in 0.3% saline.  
Placebo injection will be provided in [ADDRESS_592556] 
the labeled volume of 1 mL of 1.5 Î¼g/mL of riboflavin in 0.9% sodium chloride. 
Both RGLS8429 and placebo solutions are clear and colorless to pale yellow.  
Study Rationale:  
ADPKD is a monogenic systemic disease char acterized by [CONTACT_462818], bilateral 
enlargement of fluid-filled polycystic kidneys wher e increase in total kidney volume occurs long 
before detectable decline of renal function. Fifty percent of ADPKD patients develop end-stage 
renal disease (ESRD) by [CONTACT_14898] 60, accounting for 5% of all ESRD patients in the [LOCATION_002] 
(US) requiring renal replacement therapy such as dialysis or transplant.  
RGLS8429 is a potent and selective anti-miR-17 oligo nucleotide that dose-dependently inhibits the 
function of miR-17 in kidney cells in vitro and in  animal models of polycystic kidney disease 
(PKD) in vivo. The expression of the miR-17 fa mily of microRNAs has been shown to be 
increased in kidney samples from both mous e ADPKD models and patients with ADPKD. Kidney-
specific knockdown of the miR-17~92 cluster attenu ates disease progression and increases overall 
survival in multiple transgenic  mouse models of PKD and su bcutaneous (SC) dosing with 
RGLS8429 resulted in improvement in two di fferent mouse models of PKD. In the Pkd1F/RC mouse 
model, RGLS8429 significantly reduced kidney weight-to-body weight ratio, serum blood urea 
nitrogen (BUN), kidney cyst index, a nd kidney cyst proliferation. In the Pcy/DBA mouse model, 
RGLS8429 significantly reduced kidney weight-to-bo dy weight ratio, Taken together, these studies 
demonstrate that miR-17 is a promising ther apeutic target for the treatment of ADPKD. 
Study Objectives: 
Primary Objective 
x To assess the safety and tolerability of  single ascending doses of RGLS8429  
RGLS8429  
Protocol RGLS8429-01 v3.0  Regul us Therapeutics Inc. 
Confidential and Proprietary 7 6 June 2022 Secondary Objectives 
x To identify dose-limiting toxicity (DLT) a nd to determine the maximum tolerated dose 
(MTD) of a single SC dose of RGLS8429 
x To characterize the pharmacokinetic (PK) properties of RGLS8429 
Exploratory Objective 
x To characterize multiple potential renal biomarkers  
Study Endpoints: 
Primary Endpoint 
x Incidence of adverse events (AEs) and change in  safety laboratory test results, vital signs, 
Scale for the Assessment and Rating of Ataxia (SARA), and electrocardiogram (ECG) 
parameters and Holter monitoring over time  
Secondary Endpoints 
x Incidence of DLT and determination of MTD 
x PK parameters of RGLS8429 including: 
o Maximum observed concentration (C max)  
o Time to maximum observed concentration (T max)  
o Area under the concentrationâ€“time curve up to [ADDRESS_592557] dose (AUC 0-24) 
o Area under the concentrationâ€“time curve up to the last quantifiable concentration 
(AUC 0-t) 
o Area under the concentrationâ€“time curv e extrapolated to infinity (AUC inf)  
o Half-life (t Â½)  
o Apparent clearance (CL/F)  
o Volume of distribution (V z/F) 
o Fraction of unchanged RGLS8429 excreted in the urine (fe) 
o Total amount of unchanged RGLS8429 excreted in the urine (Ae) 
Exploratory Endpoints 
x Characterize multiple potential renal biomarke rs in urine (e.g., polycystin 1 [PC1], 
polycystin 2 [PC2], neutrophil gelatinase-a ssociated lipocalin [NGAL], kidney injury 
molecule-1 [KIM-1], monocyte chemoattractan t protein-1 [MCP-1], beta-2 microglobulin 
[B2M], and clusterin [CLU]) and in serum (e.g ., Cystatin-C, Insulin-like Growth Factor 
Binding Protein Acid Labile Subunit [IGFALS], albumin [Alb], copeptin [CT-proAVP], 
N-acetyl-1-methylhistidine, and others)  
Study Design and Methodology: 
In this randomized, double-blind, placebo-controll ed Phase 1 study, a single ascending dose of 
RGLS8429 or placebo will be administered via SC inj ection to healthy volunteers to evaluate the 
safety, tolerability, and PK of RGLS8429.  
RGLS8429  
Protocol RGLS8429-01 v3.0  Regul us Therapeutics Inc. 
Confidential and Proprietary 8 6 June 2022 Eight subjects will be randomized 3:1 RGLS8429:Pl acebo into each of 4 sequential cohorts (32 
subjects in total).  
Cohort 1  0.5 mg/kg RGLS8429 or placebo 
Cohort 2 1.0 mg/kg RGLS8429 or placebo 
Cohort 3  2.0 mg/kg RGLS8429 or placebo 
Cohort 4 4.0 mg/kg RGLS8429 or placebo 
In each cohort, 6 subjects will be randomized to  receive RGLS8429 and 2 will be randomized to 
receive placebo. Enrollment into subsequent cohorts will be initiate d after review of safety (AEs 
and safety laboratory tests) from the prior cohort. 
For Cohort 1, the first two subjects will receive RGLS8429 or placebo (randomized such that one 
subject receives RGLS8429 and one receives placebo) and this sentinel grou p will be monitored for 
[ADDRESS_592558] will be responsible fo r preparing RGLS8429 or placebo and providing 
the study drug to blinded study personnel for administration according to the randomization 
procedures.  
Subjects will be admitted to the study center on Da y -1, one day prior to the day of study drug 
administration (Day 1), and will be discharged on Da y 2, no less than 6 hr after the collection of 
the 24-hr PK sample. Subjects will be followed for a total of 4 weeks after dosing and will return to 
the site for follow-up visits weekly from Weeks 1 through 4. The sentinel subjects will remain in 
the clinic for 48 hr after dosing. 
Dose Escalation and Stoppi[INVESTIGATOR_1869]: 
Prior to dose escalation, the Sponsor and the In vestigator will perform a blinded review of the 
safety data (e.g., AE and safety laboratory tests th rough Day 15) for all subjects at the current dose 
level to make a dose escalation decision.  
If 2 or PRUHVXEMHFWVDWWKHVDPHGRVHO HYHOH[SHULHQFHWKHVDPHRUVLP LODU*UDGHÂ•$(V
LQFOXGLQJFOLQLFDOO\VLJQLILFDQW ODERUDWRU\$(VRULIVXEMH FWH[SHULHQFHVD*UDGHÂ•$(RUD
serious adverse event (SAE) judged to be related to study drug, the Sponsor â€™s Lead Physician will 
be unblinded to the treatment. Also, if [ADDRESS_592559] develops stage 2 
AKI the Sponsorâ€™s Lead Physician will be unblinded to the treatment. 
The Sponsorâ€™s Lead Physician will determine whethe r the nature, severity, or number of event(s) 
warrants: 
1. Continuing with the study as planned 
2. Continuing with the study, but add additional safety evaluation(s) 
3. Suspend dose escalation and enroll addition al subjects at the same dose level 
4. Add an intermediate-dose cohort or adjust the next dose level 
5. Suspend or terminate the study 
Study Population:  
Approximately [ADDRESS_592560] 3 months 
prior to dosing 
3. Body mass index (BMI) 18 to 35 kg/m2 
4. Medically healthy, with no clinically significant medical history in the opi[INVESTIGATOR_684] 
5. Estimated glomerular filtration rate (eGFR) Â• 90 mL/min/1.73 m2 (see Section  2.3.3)  
6. Platelet count within the normal limits 
7. Hemoglobin concentration within the normal limits 
8. Liver function tests (alanine aminotransfera se [ALT], aspartate aminotransferase [AST], 
alkaline phos SKDWDVH>$/3@DQGELOLUXELQ>WRWDODQGGLUHFW@PXVWEHÂ”  the upper limit of 
normal (ULN)  
9. Female subjects of childbearing potential must not be lactating and must have no plans to 
become pregnant during the course of the study through [ADDRESS_592561] agree to use 
one of the following methods of contraception consid ered to be highly effective (i.e., results in 
<1% failure rate when used consistently and correctly) from Screening through 28 days after 
the administration of study drug 
a. Intrauterine device (IUD) or intrauterine system  (IUS) in place for at least [ADDRESS_592562] of childbearing potential 
and had his vasectomy performed 6 months  or more prior to randomization. 
c. Stable hormonal contraception associated with  inhibition of ovulation (with approved oral, 
transdermal, or depot [e.g., NuvaRing, depot in jection, etc.] regimen) for at least [ADDRESS_592563] 6 months prior to the administration of study drug: 
a. Hysterectomy  
b. Bilateral oophorectomy  
c. Bilateral tubal occlusion 
d. Bilateral salpi[INVESTIGATOR_462801] [ADDRESS_592564]  agree to use a condom with spermicide or 
abstain from sexual intercourse from Day 1 until 28 days after the administration of study drug. 
(No restrictions are required for a vasectomized  heterosexual male prov ided his vasectomy was 
performed [ADDRESS_592565] follow the same restrictions as a non-
vasectomized heterosexual male.) 
12. Male and female subjects must agree not to donate  sperm or preserve eggs (ova), respectively, 
from Day [ADDRESS_592566] agree not to donate blood in the 28 days prior to randomization or plasma in the 7 days 
prior to randomization through the end of study (EOS) visit 
14. Seated blood pressure (systolic/diastolic) is Â• 90/40 mmHg and Â” 140/90 mmHg 
15. Seated heart rate is Â• 40 bpm and Â”99 bpm 
16. Fridericia-corrected QT (QTcF) interval is < 460 msec (males) or < 480 msec (females) and 
without any ECG findings deemed clini cally significant by [CONTACT_737] 
17. Must understand and consent to the study procedur es explained in the informed consent form 
(ICF) and be willing and able to  comply with the protocol 
Exclusion Criteria 
1. Subject is mentally incapacitated or has significant emotional problems 
2. Any medical condition or social circumstance that, in the opi[INVESTIGATOR_689], may 
make the subject unlikely to complete the study or comply with study procedures and 
requirements, or may pose a risk to the subjectâ€™s safety 
3. History of malignancy, except for successfully treated squamous or basal cell carcinoma skin 
cancer  
4. History or presence of opportunistic infection, in the opi[INVESTIGATOR_689] 
5. History or presence of any clinically significan t local infection (e.g., cellulitis, abscess) or 
systemic infection (e.g., septicemia) within 3 months prior to Screening 
6. Fever (body temperature Â• 100.4Â°F) or symptomatic viral or b acterial infection within [ADDRESS_592567] 2 years prior to Screening 
9. Positive urine drug or alcohol results  
10. +DVÂ•SURWHLQRQXULQHGLSVWLFN  
11. Positive results at Screening for human immuno deficiency virus (HIV), hepatitis B surface 
antigen (HBsAg), or hepatitis C virus (HCV) antibody 
12. Positive urine cotinine  
13. Unable to refrain from, or anticipates the use of, any drug, including prescription and 
non-prescription medications and herbal remedi es, from 14 days prior to dosing until 
completion of the EOS visit, except as approved by [CONTACT_737]  
14. History of any major surgical procedure with in 3 months prior to dosing (excluding minor 
cosmetic surgery or minor dental procedures) 
RGLS8429  
Protocol RGLS8429-01 v3.0  Regul us Therapeutics Inc. 
Confidential and Proprietary 11 6 June 2022 15. Subjects with tattoo(s) or scarring at or near the site of SC injection or any other condition that 
may interfere with injection site examination(s), in the opi[INVESTIGATOR_689] 
16. Participation in another clinical trial and/or exposure to any investigational drug or approved 
therapy for investigational use within 28 days or 5 half-lives of the investigational drugâ€™s 
dosing, whichever is longer, prior to dosing.  The 28-day and 5-half-life windows will be 
calculated from the date of the last dosing in th e previous study to Day 1 of the current study. 
Statistical Methods: 
Tabular summaries and analysis results will be ge nerated by [CONTACT_462819]8429 and placebo 
(pooled across all cohorts). Descriptive statistic s by [CONTACT_462820]. 
Sample Size  
Formal sample size calculations were not performe d for this study. The dose cohort size is 8 
subjects randomized 3:1 to RGLS8429 versus placebo. The size of each dose cohort was chosen to 
provide sufficient information to allow assessment of the safety and tolerability of RGLS8429.  
Safety Analysis  
Safety data (e.g., frequencies of treatment-eme rgent adverse events [TEAEs] and SAEs, changes 
from baseline in SARA test scores , safety laboratory test results, vital signs, ECG parameters and 
Holter monitoring) will be summarized descriptiv ely by [CONTACT_462821], as 
appropriate. No formal statistical tests will be co nducted to assess the safety or tolerability of 
RGLS8429.  
Pharmacokinetic Analysis 
PK samples will be analyzed for RGLS8429 concentration using a validated, sensitive, specific 
bioanalytical method. The laboratory analyzing th e PK samples will be unblinded, so PK analysis 
is performed only on subjects re ceiving RGLS8429. Placebo samples will be analyzed if necessary. 
Using non-compartmental methods, the plasma and urine concentration versus time data will be 
used to derive the following PK parameters: C max, Tmax, AUC 0-24, AUC 0-t, AUC inf, tÂ½, CL/F, V z/F, 
fe, and Ae.  
Dose proportionality will be explored using the power model for C max, AUC 0-24, AUC 0-t, and 
AUC inf s data permit. 
Biomarker Analysis 
Descriptive statistics will be used to characteriz e urine (e.g., PC1, PC2, NGAL, KIM-1, MCP-1, 
B2M, and CLU) and serum (e.g., Cystatin -C, IGFALS, Alb, CT-proAVP, N-acetyl-1-
methylhistidine, and others) biomarkers in all subjects .  
 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 12 6 June 2022  Table 1: Schedule of Assessments and Procedures  
 Screen 1 Treatment Follow-Up 
Week     1 2 3 4/EOS 
Days -[ADDRESS_592568] 12 X X                 X 
Urine Drug and Alcohol Screen X X                 X 
HBsAg, HCV, HIV Screen X                   
Inclusion/Exclusion Review X X                  
Randomization  X                  
SARA Assessment 13   X     X     X    X 
Adverse Events   X X X X X 
Concomitant Medications X X X X X X X 
Study Drug Administration   X                 
PK Plasma Collection 14, 19   X   X  X  X X  X  X  X   
24-Hr Urine Collection 15, 19   X     
Serum biomarkers 16, 19 X X                  
Urine biomarkers 17, 19 X X                  
Holter monitoring 18   X     
Admission to Clinic  X                  
Discharge from Clinic               X     
Clinic Visit                X X X X 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 13 6 June 2022  Abbreviations: ECG, electrocardio gram; EOS, end of study or early termination vi sit; HBsAg, hepatitis B surface antigen; HCV, h epatitis C virus; HIV, human 
immunodeficiency virus; PK, pharmacokinetics; SARA=Scale for the Assessment and Rating of Ataxia.  
1 Screening Period within 28 days prior to study drug administration (Baseline = Day -[ADDRESS_592569]/procedure performed). 
2 Ensure that all Day 1 procedures scheduled to be completed prior to dosing are completed prior to dosing. 
3 Complete physical examination at Screening and Week 4/EOS Visit. Limited physical examination at other visits. The limited phys ical examination will 
be focused on general appearance, the respi[INVESTIGATOR_696], neurological, and cardiovascular systems, and subject-reported symptoms  
4 Measure weight at all visits indicated. Height at  Screening only. Calculate BMI at Screening Visit. 
5 Systolic (SBP) and diastolic (DBP) blood pressure measurements, heart rate (HR), body temperature, and respi[INVESTIGATOR_697] (RR). 
[ADDRESS_592570] new or worsening clinically significant abnormalities as an AE. 
7 Full hematology panel including hemoglobin (Hb), hematocr it (Hct), red blood cell (RBC) count,  red cell indice s, white blood ce ll (WBC) count including 
absolute cell counts, with diff erential, and platelet count. 
8 Fasting chemistry panel including total protein, glucose, uric acid, creatine kinase (CK), lactate dehydrogenase (LDH), sodium,  potassium, chloride, 
bicarbonate, calcium, phosphate, BUN, creatinine (Scr), and hepatic function panel (albumin, total bilirubin, direct bilirubin,  ALT, AST, ALP, and gamma-
glutamyl transf erase [GGT]). 
9 Prothrombin time (PT), activated partial thromboplastin time (aPT T), international normalized rati o (INR), and fibrinogen will be collected on Day -1; 
Day 1, [ADDRESS_592571]-dose; and Day 2, [ADDRESS_592572]-dose; and at Week 4/EOS.  
10 Urinalysis panel including specific gravity, pH, protein, glucose, ketones, blood (Hb), leukocyte esterase nitrite, bilirubin, and urobilinogen. If protein, 
blood, or leukocyte esterase nitrate parameters are ab normal a microscopic examinat ion will be completed.  
11 Fasting lipid panel including total cholesterol, triglycerides, high-density lipoprotein (HDL), and low-density lipoprotein (LD L). 
[ADDRESS_592573]-dose on Day 1; on Day 2, 1 hr after the 24-hr PK sample collectio n; and at Week 4/EOS 
Visit. 
[ADDRESS_592574]-dose plasma samples should be obt ained within the 
following time margins: collections at 2, 4, 6, and 8 hr Â±15 minutes, 12 hr Â±30 minutes, and 24 hr Â±60 minutes.  
15 24-hr urine collection for PK analysis will begin immediately after study drug dosing on Day 1 (0-24 hr). The subject should vo id immediately before 
dosing (before the 24-hr urine collection is started). Last void will be at [ADDRESS_592575] dose.  
16 Serum sample for exploratory biomarkers (e .g., Cystatin-C, IGFALS, Alb,  CT-pro-AVP, N-acetyl-1-methyl histidine, and others).  
[ADDRESS_592576] 150 mL ( more if possible ) of mid-stream free-flow urine for analysis of exploratory biomarkers (e.g., PC1, PC2, NGAL, KIM-1, MCP-1, 
B2M, and CLU during Screening and on Day -1. These samples must NOT be the first urination of the day (to avoid too much debris  in the sample). 
18 Start Holter monitoring 1 hr before study drug administration on Day 1 and continue for 30 minutes after the 24-hr PK sample is  obtained on Day 2. 
19 Unused backup plasma, serum, and urine PK/biomarker samples may also be used for additional exploratory biomarkers analysis. 
 
 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592577] ....................................................................25  
2.3.10.  HBsAg, HCV Antibody, and HIV-1/2 Antibodies Screening Tests ..........................25  
2.3.11.  Scale for the Assessment and Rating of Ataxia (SARA) ...........................................25  
2.3.12.  Pharmacokinetic Samples ...........................................................................................25  
2.3.13.  Serum Biomarkers ......................................................................................................25  
2.3.14.  Urine Biomarkers ........................................................................................................26  
2.3.15.  Exploratory Biomarkers ..............................................................................................26  
3. STUDY DESIGN .......................................................................................................27  
3.1. Overview of Study Design ..........................................................................................27  
3.2. Dose Escalation and Stoppi[INVESTIGATOR_1869] ..........................................................................27  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 15 6 June 2022  3.3. Study Duration for Subjects ........................................................................................28  
3.4. End of Trial .................................................................................................................2 8 
4. STUDY POPULATION .............................................................................................29  
4.1. Number of Subjects ....................................................................................................29  
4.2. Inclusion Criteria ........................................................................................................29  
4.3. Exclusion Criteria .......................................................................................................30  
5. STUDY VISITS ..........................................................................................................32  
5.1. Screening Period (Day -28 to Day -1) ........................................................................32  
5.2. Treatment Period (Day 1 and Day 2) ..........................................................................33  
5.3. Follow-Up Period (Day 3 to Day 29) .........................................................................33  
5.3.1.  Follow-Up Visit (Day 8) .............................................................................................33  
5.3.2.  Follow-Up Visit (Day 15) ...........................................................................................34  
5.3.3.  Follow-Up Visit (Day 22) ...........................................................................................34  
5.3.4.  Follow-Up / End of Study [EOS] Visit (Day 29) .......................................................[ADDRESS_592578] Identificati on and Randomization ..................................................................36  
6.5. Preparation and Dispensing ........................................................................................37  
7. CONCOMITANT MEDICATION S AND PROCEDURES ......................................38  
7.1. Permitted Concomitant Medi cations and Procedures .................................................38  
7.2. Prohibited Concomitant Medi cations and Procedures ................................................38  
8. DATA ANALYSIS / STATISTICAL METHODS ....................................................39  
8.1. General Considerations ...............................................................................................39  
8.2. Sample Size Determination ........................................................................................39  
8.3. Analysis Populations, Subgroups, and Covariates .....................................................39  
8.3.1.  Analysis Populations ..................................................................................................39  
8.4. Final Analysis .............................................................................................................39  
8.4.1.  Disposition ..................................................................................................................4 0 
8.4.2.  Demographic and Baseline Characteristics ................................................................40  
8.4.4.  Pharmacokinetic Analysis ..........................................................................................41  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 16 6 June 2022  8.4.5.  Biomarker Analysis ....................................................................................................41  
9. ADVERSE EVENTS ..................................................................................................42  
9.1. Monitoring, Recording and Repor ting of Adverse Events .........................................42  
9.2. Evaluation of Adverse Events ....................................................................................42  
9.2.1.  Seriousness .................................................................................................................42  
9.2.2.  Severity/Intensity ........................................................................................................[ADDRESS_592579]/Independent Ethics Committee Review and Approval ..[ADDRESS_592580]/ Ethics Committee .................52  
12.8.  Termination of the Study ............................................................................................52  
13. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] .......................................................53  
13.1.  Data/Documents .........................................................................................................[ADDRESS_592581] Retention ........................................................................................................53  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 17 6 June 2022  14. QUALITY CONTROL AND QUALITY ASSURANCE .........................................55  
14.1.  Study Monitoring and Source Data Verification ........................................................55  
14.2.  Audits and Inspections ................................................................................................55  
15. PUBLICATIONS .......................................................................................................56  
16. REFERENCES ...........................................................................................................57  
APPENDIX A.  TABLE OF ABBREVIATIONS .......................................................................58  
APPENDIX B.  SCALE FOR THE ASSESSMENT AND RATING OF ATAXIA (SARA) ....[ADDRESS_592582] OF TABLES 
Table 1:  Schedule of Assessments  and Procedures ..................................................................12  
Table 2:  Safety Laboratory Tests ..............................................................................................[ADDRESS_592583] common form of polycystic kidney disease (PKD), is  a monogenic systemic disease 
driven mostly by [CONTACT_462822]1  or PKD2  genes, leading to re duced expression and/or 
function of their encoded-proteins polycystin-1 (PC1) and/or polycysti n-2 (PC2), excessive proliferation 
of the renal tubular ep ithelium and formation of multiple cysts ( Torres, 2009 ; Chapman, 2015 ). Indeed, 
PC1 and PC2 levels in patientsâ€™ ur inary exosomes were shown to corr elate inversely w ith the height-
adjusted total kidney volume ( Hogan, 2015 ). ADPKD is characterized by [CONTACT_462823], bilateral 
enlargement of the fluid-filled pol ycystic kidneys, with kidney volume increasing long before detectable 
decline of kidney function. In addi tion to renal cysts, extrarenal cy sts can also develop in the liver, 
pancreas, seminal vesicles, and arachnoid. Typi[INVESTIGATOR_462802], hematuria, proteinuria, 
renal colic, urinary tract infec tion, hypertension, and intracranial aneurysms. Fifty percent of ADPKD 
patients develop end-stage renal disease by [CONTACT_14898] 60, accounting for 5% of all end-stage renal 
disease patients in the [LOCATION_002] (US) requiri ng renal replacement therapy such as dialysis or 
transplant ( Chebib, 2016 ). 
1.2. miR-[ADDRESS_592584] target genes of miR-
17 (Patel, 2013 ). Increased miR-17 expression has been de tected in kidney samples from both mouse 
ADPKD models and human ADPKD patients ( Hajarnis, 2017 ). Kidney-specific overexpression of miR-
17~92 repressed Pkd1  and Pkd2  expression and produced kidney cysts in mice ( Patel, 2013 ), whereas 
genetic knockdown of miR-17~92 attenuated disease pr ogression in multiple mouse models of PKD 
(Patel, 2013  and Hajarnis, 2017 ). Importantly, inhibition of miR-[ADDRESS_592585] cultures ( Hajarnis, 2017  and Lee, 
2019 ), whereas re-expression of PC1 and PC2 has been  shown to rapi[INVESTIGATOR_462803], 
cell proliferation, fibrosis, and infl ammation in mouse models of ADPKD ( Dong, 2021 ). Therefore, 
preferential targeting of the mi R-[ADDRESS_592586] culture samples in vitro  
(Hajarnis, 2017  and Lee, 2019 ). Moreover, miR-17 inhibition has b een shown to improve expression of 
pathogenic gene networks and pathways in PKD, including de-repression of messenger RNA (mRNA) 
of Pkd1  and Pkd2  genes in mouse models of ADPKD. The coordinated alterati on of the polycystic 
kidney transcriptome towards a normal kidney profile following miR -17 inhibition exemplifies the 
potential of an anti-miR-17 oligonucleotide as a disease-mo difying treatment for ADPKD ( Lee, 2019 ). 
Importantly, recent data from the fi rst cohort of a Phase 1b clinical  trial ([STUDY_ID_REMOVED]) demonstrated 
clinical evidence that trea tment with RGLS4326 increased urinary PC1 and PC2 level ( Lee, 2021 ) in 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 19 6 June 2022  patients with ADPKD, likely throug h inhibition of miR-17 in the ki dney. These results imply ongoing 
cis-repression of PC1 and PC2 by [CONTACT_462824]-17 in ADPKD patients prior to treatment with 
anti-miR-17, further vali dating miR-17 as a therapeutic target for ADPKD. 
1.3. Nonclinical Pharmacokinetics , Pharmacology, and Toxicology 
The following is a brief summary of the Nonclinical information. Please see the RGLS8429 
Investigatorâ€™s Brochure for a more detail ed presentation of this information.  
In nonclinical ADPKD efficacy studies, RGLS8429 tr eatment reduced disease progression in both 
Pkd1F/RC and Pcy/DBA mouse models. In the Pkd1F/RC mouse model, RGLS8429 caused a significant 
reduction in kidney weight -to-body weight ratio, serum blood urea nitrogen (BUN), kidney cyst index, 
and kidney cyst proliferation. In the Pcy/DBA mouse model, RGLS8429 re duced kidney weight-to-body 
weight ratio significantly. In a ddition, the combination of RGLS 8429 and tolvaptan demonstrated a 
greater reduction in disease progres sion than either drug alone in the  Pcy/DBA mouse model. 
Based on in silico bioinformatics analysis and in vitro receptor binding studies, RGLS8429 appears to 
have low potential for off-targe t effects towards ribonucleic acid  (RNA) and receptor targets. 
RGLS8429 had no effects on cardiovas cular, respi[INVESTIGATOR_696], and central  nervous system function at 
supraclinical concentrations a nd dose levels in animals. RGLS8429 had no meaningful effect on the 
human ether-Ã -go-go-related gene (hER G) potassium channels in vitro. 
In nonclinical PK and toxicokine tic studies, SC administration of  RGLS8429 demonstrated rapid 
absorption (time to maximum concentration [T max] 1-2 hr) followed by [CONTACT_462825].  
The plasma t 1/2 in mice (~ 2 hr) whereas t 1/2 ranged between 6 -7 hr in monkeys. 
Plasma exposure increased in a generally dose -proportional manner across all dose levels, and no 
meaningful accumulation was observed in mice or monkeys. RGLS8429 is highly bound to plasma 
protein in mice, monkeys and humans, monkeys, and mice (79.1% ,86.6%, and 81.6 %, respectively). 
RGLS8429 distributes rapi[INVESTIGATOR_462804], is metabolically stab le with only trace amounts of 
metabolites measured, and is  excreted rapi[INVESTIGATOR_462805], primar ily in the first [ADDRESS_592587] ions with other drugs via 
either cytochrome P450 enzymes or transporters. In Pcy/DBA mouse model, co-administration of 
RGLS8429 and tolvaptan had no signif icant effect (defined as <2-fo ld change) on tolvaptan PK in 
plasma and RGLS8429 PK in kidney and liver. 
Toxicity studies of RGLS8429 comple ted to date demonstrate that RG LS8429 is not acutely toxic at up 
to 2000 mg/kg in mice.  
In a 13-week Good Laboratory Practice (GLP) toxici ty study in CD-1 mice evaluating 60, 300 and 600 
mg/kg weekly of RGLS8429, the no observed adverse effects level ( NOAEL) was determined to be 60 
mg/kg, with dose-limiting hepatotoxicity at highe r dose levels. Minimal single-cell hepatocellular 
necrosis with [ADDRESS_592588] were observed at 6 00 mg/kg; in addition, one 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 20 6 June 2022  mouse at 300 mg/kg had single-cell he patocellular necrosis in the absenc e of elevations in ALT or AST 
at that dose level. Other findi ngs at 300 mg/kg included: decr eased thymic lymphocytes with 
corresponding decreased thymus size and weight, and mild decreased red cell ma ss with compensatory 
hematopoiesis in the spleen and bone  marrow, both of which were consid ered to be anti-miR-17 effects. 
Additional changes at 300 mg/kg included transien t nose/muzzle swelling pos t-dose, decreased serum 
cholesterol, karyomegaly and increased mitotic figures of hepato cytes in the liver (correlating with 
increased liver weight), and increase d foamy macrophage infiltration in th e injection site(s), all of which 
were considered non-adverse. 
In a 13-week GLP toxicity study in cynomolgus monkeys evaluati ng 15, 75 and 150 mg/kg weekly of 
RGLS8429, highest dose of RGLS8429 ( 150 mg/kg) was well tolerated an d was determined to be the 
NOAEL. The following findings, all of which were considered to be non-adverse, include: minimal 
increases in fibrinogen, minimal but transient incr eases in activated throm boplastin time (APTT), dose-
related dark red discoloration at the injection site with microscopi c findings of fibrosis, macrophage 
infiltration, perivascular inflammation, and hemorrhag e, vacuolated macrophage s in the lymph nodes, 
and basophilic granules within Kupffer cells in the liver.  
SC administration of the clinical formulation (150 mg/kg in water for injection) was well tolerated in 
rabbits. RGLS8429 has shown no poten tial for genotoxicity in two in vitro  studies (Ames test and 
micronucleus assay).  
RGLS8429 did not cause overt cytot oxicity and showed no evidence of  mitochondrial t oxicity. Although 
certain oligonucleotides have exhi bited the propensity to cause th rombocytopenia in animals and/or 
humans, in vitro  studies suggest that RGLS8429 has minimal potential for adve rse effects on platelets, 
which is consistent with the absence of  adverse effects in mice and monkeys. 
In addition, RGLS8429 did not induce genes involved in inflammation, consistent with the low pro-
inflammatory effects observed. 
1.4. Dose Rationale 
The starting dose and dose levels  selected for first-in-human dosing are based on the NOAELs and 
toxicity profiles in the GLP 13- week toxicity studies of RGLS 8429. The NOAELs in mice and monkeys 
were 60 mg/kg and 150 mg/kg, respectively, for human equivalent doses (HED) of 5 and 48, 
respectively. Based on the HED in the more sensitiv e species (mouse) and usi ng a safety factor of 
approximately 10 (in accordance w ith FDA Guidance for Industry, Estimating the Maximum Safe 
Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers [July 2005]), the 
starting dose in this study is 0.5 mg/kg and maximum dose will not exceed 5 mg/kg. 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 21 6 June 2022  2. STUDY OBJECTIVES, ENDPOI NTS, AND ASSESSMENTS 
2.1. Study Objectives 
Primary Objective 
x To assess the safety and to lerability of single ascending SC doses of RGLS8429  
Secondary Objectives 
x To identify DLT and to determine th e MTD of a single SC dose of RGLS8429 
x To characterize the PK properties of RGLS8429 
Exploratory Objective 
x To characterize multiple pot ential renal biomarkers 
2.2. Study Endpoints 
Primary Endpoint 
x Incidence of adverse events (AEs) and change in  safety laboratory test results, vital signs, 
SARA, and ECG parameters a nd Holter monitoring over time 
Secondary Endpoints 
x Incidence of DLT and determination of MTD 
x PK parameters of RGLS8429 including: 
o Maximum observed concentration (C max)  
o Time to maximum observed concentration (T max) 
o Area under the concentrationâ€“time curve up to [ADDRESS_592589] dose (AUC 0-24) 
o Area under the concentrationâ€“time  curve up to the last qu antifiable concentration 
(AUC 0-t) 
o Area under the concentrationâ€“time curv e extrapolated to infinity (AUC inf)  
o Half-life (t Â½)  
o Apparent clearance (CL/F)  
o Volume of distribution (V z/F) 
o Fraction of unchanged RGLS8429 ex creted in the urine (fe) 
o Total amount of unchanged RGLS84 29 excreted in the urine (Ae) 
Exploratory Endpoints 
x Characterize multiple potentia l renal biomarkers in urine (e.g., PC2, NGAL, KIM-1, MCP-1, 
B2M, and CLU) and in serum (e.g., Cystatin-C, IGFALS, Alb, CT-proAVP, N-acetyl-1-
methylhistidine, and others) 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592590]â€™s medical history, and prior/current 
concomitant medications and medical procedures will be conducted according to the Schedule of 
Assessments and Procedures (see Table 1)  to ensure all study entry criteria are met. 
2.3.2.  Physical Examinations 
Physical examinations may be condu cted by a physician or another medi cally qualified individual such 
as a physician's assistant or a nurse practitioner according to the Schedule of Assessments and 
Procedures (see Table 1) . All physical examinations must include  a complete neurologic exam. A full 
physical examination will include general appearance, head, ears, ey es, nose, mouth, skin, heart, lung, 
lymph nodes, and the gastrointestinal, musculoskele tal, respi[INVESTIGATOR_696], and neur ological systems. The 
limited physical examination will be  focused on general appearance, th e respi[INVESTIGATOR_696], th e neurological, 
and cardiovascular systems, a nd subject-reported symptoms.  
2.3.3.  eGFR Calculation 
The Investigator will calculate th e estimated glomerular filtration rate (eGFR)  using the 2021 (chronic 
kidney disease epi[INVESTIGATOR_462806]) CKD-EPI [INVESTIGATOR_462807], Age, Sex Equation ( Inker, 
2021 ) during Screening: 
142 x min(Scr/k,1)Ä® x max(Scr/k,1)-1.200 0.9938age x 1.012 [if female]  
Scr is serum creatinine k is 0.7 for females and 0.9 males Ä®LV-0.241 for females a nd -0.302 for males 
min indicates the minimum of Scr/k or 1 max indicates the maximum of Scr/k or 1 
2.3.4.  Height and Weight Measurements 
Height will be recorded  only during Screening. 
Weight will be measured according to the Sche dule of Assessments and Procedures (see Table1). For 
measuring weight, a scale with appr opriate range and resolu tion should be used and must be placed on a 
stable, flat surface. Subjects must re move shoes, bulky layers of clothing , and jackets so that only light 
clothing remains. Subjects must also  remove the contents of their poc kets and should remain still during 
measurement of weight.  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 23 6 June 2022  2.3.5.  Vital Signs 
Body temperature, seated systolic and diastolic blood pr essure (BP), heart rate (H R), and respi[INVESTIGATOR_697] 
(RR) will be measured at times specified in the Schedule of Assessments and Procedures (see Table 1) .  
Body temperature may be measured or ally, via the external auditory canal, or vi a the temporal artery 
(forehead). Temperature should be measured in a consistent manne r for each subject throughout the 
entire study. 
The use of an automated device for measuring BP a nd HR is acceptable. For BPs, a properly sized and 
calibrated BP cuff should be used for each measurem ent. Subjects should be seated for approximately [ADDRESS_592591]â€™s feet flat on the floor, 
back supported, and arm supported at the level of the heart. The BP should be recorded to the nearest 
millimeters of mercury (mmHg).  
When the timing of these measuremen ts coincides with a blood sample collection, obtain the vital signs, 
and then collect the blood sample.  
2.3.6.  ECGs and Holter Monitoring 
ECGs and Holter monitoring should be  obtained at times specified in the Schedule of Assessments and 
Procedures (see Table 1) . 
The Investigator or a medically qualified designee should review a ll ECGs obtained during the study. 
Consultation with a cardiologist should be obtained if necessary. R ecord new or worsening clinically 
significant abnormalities as an AE. Po st-treatment ECG results should be compared with the pre-dose 
ECG assessments. 
Holter monitoring should be perform ed by [CONTACT_29517] a medi cally qualified designee at times 
specified in the Schedule of A ssessments and Procedures (see Table 1) . The Holter data will be analyzed 
centrally, and the independe nt central reader will remain bl inded to treatment group. Throughout the 
duration of Holter monitoring, othe r procedures and SARA assessmen t may occur. At the specified 
timepoints, the procedures will be performed in this  order: ECG, vital signs, PK and/or other blood 
collection, and then fo llowed by [CONTACT_462826]. Details an d procedures will be provided in the 
Holter Monitoring Manual. 
2.3.7.  Safety Laboratory Tests 
The Safety Laboratory Tests listed in  Table 2 should be obtained at the times  specified in the Schedule 
of Assessments and Procedures (see Table 1) . Detailed collection, proces sing, storage, and shipment 
instructions will be provide d in a Laboratory Manual. 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 24 6 June 2022  Table 2: Safety Laboratory Tests 
Hematology â€“ Complete Blood Count 
x Hemoglobin (Hb) 
x Hematocrit (Hct) 
x Red Blood Cell (RBC) Count 
x Mean Corpuscular Volume (MCV) 
x Mean Corpuscular Hemoglobin (MCH) 
x Mean Corpuscular Hemoglobin Concentration 
(MCHC) x Platelet Count 
x White Blood Cell (WBC) Count and 
Differential 
x Absolute Neutrophil Count 
x Absolute Lymphocyte Count 
x Absolute Monocyte Count 
x Absolute Eosinophil Count 
x Absolute Basophil Count 
Chemistry â€“ Metabolic Panel 
x Glucose 
x Calcium 
x Albumin (Alb) 
x Total Protein  
x Sodium 
x Potassium 
x Bicarbonate (Total CO 2) 
x Chloride 
x Blood Urea Nitrogen (BUN) 
x Uric Acid 
x Creatine kinase (CK) x Phosphate 
x Lactate Dehydrogenase (LDH) 
x Blood Urea Nitrogen (BUN) 
x Creatinine (Scr) 
x Alkaline Phosphatase (ALP) 
x Alanine Aminotransferase (ALT) 
x Aspartate Aminotransferase (AST) 
x Gamma-Glutamyl Transferase (GGT) 
x Total Bilirubin  
x Direct Bilirubin 
Urinalysis a 
x Specific Gravity 
x pH 
x Protein  
x Glucose 
x Ketones x Blood (Hemoglobin) 
x Leukocyte Esterase Nitrite 
x Bilirubin 
x Urobilinogen 
x Microscopic Examination b 
Coagulation 
x International Normalized Ratio (INR) 
x Prothrombin Time (PT) x Activated Partial Thromb oplastin Time (aPTT) 
x Fibrinogen 
Lipi[INVESTIGATOR_805] 
x Total cholesterol 
x Triglycerides x High-density Lipoprotein (HDL) 
x Low-density Lipoprotein (LDL) 
Unscheduled safety laboratory assessments may be obtained at any time during the study to assess potential safety concerns. 
a Urinalysis testing will be conducted using standard commercial test strips (urine dipstick).  
b Only if urine dipstick is positive for blood, protein, or leukocyte esterase nitrate.  
2.3.8.  Pregnancy Test 
For female subjects of childbearing potential, a se rum pregnancy test will be performed at Screening. 
Urine pregnancy tests will be performed at the remaining specified visits according to the Schedule of 
Assessments and Procedures (see Table 1) . A positive urine pregnancy test  will be confirmed with a 
serum pregnancy test. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592592] 
The drug and alcohol screen will include measurem ent of opi[INVESTIGATOR_858], cocaine, heroin, phencyclidine, 
amphetamines (including ecstasy), barbiturates, benzodiazepi[INVESTIGATOR_1651], can nabinoids, and al cohol according 
to the Schedule of Assess ments and Procedures (see Table 1) . 
2.3.10.  HBsAg, HCV Antibody, and HIV-1/2 Antibodies Screening Tests 
All subjects will be tested for HB sAg, HCV antibody, and HIV-1/2 antibodies  at Screening. 
2.3.11.  Scale for the Assessment and Rating of Ataxia (SARA) 
The SARA test is used in this study to detect pos sible central nervous syst em impairment by [CONTACT_462827] (see Table 1) . 
When timepoints to perform the SARA assessmen t are near timepoints fo r other procedures, the 
procedures will be performed in th is order: ECG, vital signs, PK a nd/or other blood collection, and then 
followed by [CONTACT_462826]. The test should be performed by [CONTACT_462828] e same individual during 
the study to minimize the va riability in how the test is performed and scored. The scale is presented in 
Appendix B . 
2.3.12.  Pharmacokinetic Samples 
Plasma PK samples will be collect ed at the times specified in the Schedule of Assessments and 
Procedures (see Table 1) .  
All efforts should be made to obtain PK samples at the specified nominal t ime relative to dosing. Pre-
dose plasma PK sample on Day [ADDRESS_592593]-dose 
plasma samples should be obtained w ithin the following time margins: collections at 2, 4, 6, and 8 hr 
Â±15 minutes, 12 hr Â±30 minutes, and 24 hrÂ±[ADDRESS_592594] date and time of collection for each 
sample should be noted on the source document and in  the case report form ( CRF). Detailed collection, 
processing, storage, and shipment instructions fo r PK samples will be provided in the Laboratory 
Manual. 
24-hr urine collection for PK an alysis will begin immediately af ter study drug dosing on Day 1 (0-24 
hr). The subject should void immediately before dosi ng (before the 24-hr urine collection is started) and 
the last void will be timed for [ADDRESS_592595] serum samples during Screening and on Day -1 according to the Schedule of Assessments and 
Procedures (see Table 1)  for exploratory biomarker analysis  (e.g., Cystatin-C, IGFALS, Alb, CT-
proAVP, N-acetyl-1-methylhistidine, and others). Deta iled collection, processing, storage, and shipment 
instructions for serum biomarker samples will be provided in the Laboratory Manual. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592596] 150 mL ( more if possible ) of mid-stream free-flow urine for analysis of exploratory 
biomarkers (PC1, and PC2, NGAL , KIM-1, MCP-1, B2M, CLU) dur ing Screening and on Day -1 
according to the Schedule of Assessments and Procedures (see Table 1) . These samples must NOT be 
the first urination of the day (to avoid too much debris in the samp le). Detailed collection, processing, 
storage, and shipment instructions for urine biom arker samples will be provided in the Laboratory 
Manual. 
2.3.15.  Exploratory Biomarkers 
Residual plasma, serum, and urine sa mples (e.g., unused or backup) not ut ilized in required testing of 
PK/biomarkers will be retained and used to measure the concentrations of mul tiple potential exploratory 
renal function biomarkers in he althy volunteers. Subjects will provi de consent for the use of these 
residual samples for e xploratory tests.  
RGLS8429 
Protocol RGLS8429-[ADDRESS_592597] udy, a single ascending dose of 
RGLS8429 or placebo will be administer ed via SC injection to healthy vo lunteers to evaluate the safety, 
tolerability, and PK of RGLS8429. Eight subjects will be randomi zed 3:1 to receive RGLS8429 or 
placebo in each cohort.  
Cohort 1 0.5 mg/kg RGLS8429 or placebo Cohort 2 1.0 mg/kg RGLS8429 or placebo Cohort 3 2.0 mg/kg RGLS8429 or placebo Cohort 4 4.0 mg/kg RGLS8429 or placebo 
In each cohort, 6 subjects will be randomized to receive RGLS8429 and 2 will be randomized to receive 
placebo. Enrollment into subsequent c ohorts will be initiated after review of safety (AEs and safety 
laboratory tests) from the prior cohort.  
For Cohort 1, the first two subject s will receive RGLS8429 or place bo (randomized such that one 
subject receives RGLS8429 and one receives placebo)  and this sentinel group will be monitored for [ADDRESS_592598] will be responsible for preparing RGLS8429 or placebo and providing the 
study drug to blinded study personnel  for administration according to the randomization procedures.  
Subjects will be admitted to the study center on Day -1, one day prior to the day of study drug 
administration (Day 1), and will be discharged on Da y 2, no less than 6 hr after the collection of the 24-
hr PK sample. Subjects will be followe d for a total of 4 weeks after dosin g and will return to the site for 
follow-up visits weekly from Weeks 1 through 4. The sentinel subjects will  remain in the clinic for 48 hr 
after dosing. 
3.2. Dose Escalation and Stoppi[INVESTIGATOR_462808], the Sponsor  and the Investigator will perform a blinded review of the safety 
data (e.g., AE and safety laborator y tests through Day 15) on all subjec ts at the current dose level to 
make a dose escalation decision.  
If 2 or more subjects at the same dose level experience the sa PHRUVLPLODU*UDGHÂ•$(VLQFOXGLQJ
FOLQLFDOO\VLJQLILFDQ WODERUDWRU\$(VRU LIVXEMHFWH[SHULHQ FHVD*UDGHÂ•$(RUD6$(MXGJHGWREH
related to study drug, the Sponsorâ€™s Lead Physician will be unblinde d to the treatment. Also, if [ADDRESS_592599] develops stage 2 AKI the Sponsorâ€™s Lead Physician will be 
unblinded to the treatment. 
The Sponsorâ€™s Lead Physician will determine whethe r the nature, severity, or number of event(s) 
warrants: 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 28 6 June 2022  1. Continuing with the study as planned 
2. Continuing with the study, but add additional safety evaluation(s) 
3. Suspend dose escalation and enroll addi tional subjects at the same dose level 
4. Add an intermediate-dose cohort or adjust the next dose level 
5. Suspend or terminate the study 
3.3. Study Duration for Subjects  
Subjects will participate in the study for up to 57 days (Screening up to 28 days, Treatment 1 day, 
Follow-up 28 days). 
3.4. End of Trial 
The End of Trial is defined as either  the date of the last visit for the last subject to complete the post-
treatment follow-up, or the date of receipt of the last data point fro m a subject, whichever is the later 
date. 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 29 6 June 2022  4. STUDY POPULATION 
4.1. Number of Subjects  
Approximately 32 healthy volunteers will be enrolled. S ubjects may be replaced at the discretion of the 
Sponsor (e.g., subject noncompliance with the pr otocol, early withdrawal , missing data, etc.). 
4.2. Inclusion Criteria  
Subjects must meet the following criteria to  be eligible for st udy participation: 
1. Male or female, [ADDRESS_592600] 3 months prior 
to dosing 
3. Body mass index (BMI) 18 to 35 kg/m2 
4. Medically healthy, with no clin ically significant medical hi story in the opi[INVESTIGATOR_684]. 
5. Estimated glomerular filtration rate (eGFR) Â• 90 mL/min/1.73 m2 (see Section 2.3.3)  
6. Platelet count within the normal limit 
7. Hemoglobin concentration w ithin the normal limits 
8. Liver function tests (ALT, $67$/3DQGELOLUXELQ>WRWD ODQGGLUHFW@PXVWEHÂ”  the ULN 
9. Female subjects of childbearing potential must  not be lactating and must have no plans to 
become pregnant during the course of the study through [ADDRESS_592601] agree to use one of 
the following methods of contraception considered to be highly effective (i.e., results in <1% 
failure rate when used consistently and corre ctly) from Screening thr ough 28 days after the 
administration of study drug 
a. Intrauterine device (IUD) or in trauterine system (IUS) in place for at least [ADDRESS_592602] of 
childbearing potential and had his vasectom y performed 6 months or more prior to 
randomization. 
c. Stable hormonal contraception associated wi th inhibition of ovulation (with approved 
oral, transdermal, or depot [e.g., NuvaRing, de pot injection, etc.] re gimen) for at least 
[ADDRESS_592603] 6 months prior to administration  of study drug:  
a. Hysterectomy  
b. Bilateral oophorectomy  
c. Bilateral tubal occlusion 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592604] agree to use a c ondom with spermicide or 
abstain from sexual intercourse from Day 1 until 28 days after the administration of study drug. 
(No restrictions are required for a vasectomized  heterosexual male provided his vasectomy was 
performed [ADDRESS_592605] follow the same  restrictions as a non-
vasectomized heterosexual male.) 
12. Male and female subjects must ag ree not to donate sperm or pres erve eggs (ova), respectively, 
from Day [ADDRESS_592606] agree not to donate blood in the 28 days pr ior to randomization or plasma in the 7 days 
prior to randomizati on through the EOS visit 
14. Seated blood pressure (systolic/diastolic) is Â•  mmHg and Â” 140/90 mmHg 
15. Seated heart rate is Â• 40 bpm and Â” 99 bpm 
16. Fridericia-corrected QT (QTcF) interval is  < 460 msec (males) or < 480 msec (females) and 
without any ECG findings deemed clini cally significant by [CONTACT_737] 
17. Must understand and consent to the study procedur es explained in the in formed consent form 
(ICF) and be willing and able to  comply with the protocol 
4.3. Exclusion Criteria 
Subjects with any of the following will be excluded from participation in the study: 
1. Subject is mentally incapacitated or  has significant emotional problems 
2. Any medical condition or social circumstance that, in the opi[INVESTIGATOR_689], may make 
the subject unlikely to complete the study or comply w ith study procedures and requirements, or 
may pose a risk to th e subjectâ€™s safety 
3. History of malignancy, except for successfully treated squamous or basal cell carcinoma skin 
cancer  
4. History or presence of oppor tunistic infection, in the opi[INVESTIGATOR_689] 
5. History or presence of any clin ically significant local infec tion (e.g., cellulitis, abscess) or 
systemic infection (e.g., septicemia) w ithin 3 months prior to Screening 
6. Fever (body temperature Â• 100.4Â°F) or symptomatic viral or ba cterial infection within [ADDRESS_592607] 2 years prior to Screening 
9. Positive urine drug or alcohol results  
10. +DVÂ•S rotein on urine dipstick  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 31 6 June 2022  11. Positive results at Screening for human immun odeficiency virus (HIV), hepatitis B surface 
antigen (HBsAg), or hepatitis C virus (HCV) antibody 
12. Positive urine cotinine  
13. Unable to refrain from, or anticipates the use of, any drug, including prescription and 
non-prescription medications and herbal remedies , from 14 days prior to dosing until completion 
of the EOS visit, except as approved by [CONTACT_737]  
14. History of any major surgical procedure within 3 months pr ior to dosing (excluding minor 
cosmetic surgery or mi nor dental procedures) 
15. Subjects with tattoo(s) or scarring at or near the site of SC inj ection or any other condition that 
may interfere with injection site examination(s), in the opi[INVESTIGATOR_689] 
16. Participation in another clinical  trial and/or exposure to any investigational drug or approved 
therapy for investigational use with in 28 days or 5 half-lives of the investigational drugâ€™s dosing, 
whichever is longer, prior to dosing. The 28-day and 5-half-life windows will be calculated from 
the date of the last dosing in the prev ious study to Day [ADDRESS_592608], written informed consent will be obtained prior to any protocol-
related activities. After signing of the ICF, completion of all Screening assessme nts, and confirmation of 
eligibility, subjects will be  randomized for the study. 
5.1. Screening Period (Day -28 to Day -1) 
Subjects will be screened during th e 28 days prior to administration of  study drug (Day 1) to confirm 
that they meet the entry criteria  for the study. Some of the procedur es must occur on Day -[ADDRESS_592609] is admitted to the clinic. Subjects who fail Screen ing (i.e., do not meet en try criteria) may be 
rescreened with the approval of the Sponsorâ€™s Lead Physician.  
The following procedures are to be perfo rmed during Screening and/or Day -1: 
x Informed consent 
x Demographics (date of birth [dd mmmyyyy], sex, race, and ethnicity) 
x Medical history 
x Complete physical examination; must include a complete neurologic examination 
x Weight (Screening and Day -1) and height (Screening); calcu late BMI using Screening 
values; Day -1 weight will be used for dosing 
x Vital signs (Screening and Day -1) 
x 12 -lead ECG (Screening); Print and review 
x Safety laboratory tests (Screening and Day -1): 
o Hematology 
o Chemistry 
o Urinalysis 
o Lipi[INVESTIGATOR_805] 
x Coagulation tests (Day -1) 
x Pregnancy test, if applicable (serum at Screening; urine at and Day -1) 
x Urine drug and alcohol scr een (Screening and Day -1) 
x HBsAg, HCV, HIV-1/2 (Screening) 
x Serum biomarker sample coll ection (Screening and Day -1) 
x Urine biomarker sample colle ction (Screening and Day -1) 
x Inclusion/exclusion criteria review (Screening and Day -1) 
x Randomization after enrollmen t confirmed (Day -1) (see Section  6.4) 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 33 6 June 2022  x Concomitant medications and procedures (Screening and Day -1) 
x Admission to clinic (Day -1) 
5.2. Treatment Period (Day 1 and Day 2) 
The following procedures are to be performed on Day 1 and/or Day 2: 
x Limited physical examination (pre-dos e Day [ADDRESS_592610]-dose Day 2) 
x Vital signs (Day [ADDRESS_592611]-dose; Day 2, [ADDRESS_592612]-dose) 
x Holter monitoring should be in itiated 1 hr pre-dose and c ontinue for approximately 30 
minutes after the 24-hr PK sample is obtained (Day 1 and Day 2).  
x Print and review ECG tracings pre-do se and 4, 6, 12, and [ADDRESS_592613]-dose. 
x SARA assessment (Day [ADDRESS_592614]-dose; Day 2, [ADDRESS_592615]-dose) 
Note: The pre-dose ECG tracing and SARA pro cedures may be performed prior to the 
start of Holter monitoring at th e 1 hr pre-dose timepoint on Day 1. 
x Safety laboratory tests (Day 2, [ADDRESS_592616]-dose): 
o Hematology 
o Chemistry 
o Urinalysis 
o Lipi[INVESTIGATOR_805] 
x Coagulation test (Day 1, [ADDRESS_592617]-dose) 
x AE monitoring (Day 1 through Day 2) 
x Concomitant medications and procedures (Day 1 through Day 2) 
x Study drug administration (D ay 1 at Time Zero) 
x PK plasma samples (Day [ADDRESS_592618]-dose; Day 2, [ADDRESS_592619]-dose plasma samples should be obt ained within the foll owing time margins: 
collections at 2, 4, 6, and 8 hrÂ±15 minutes , 12 hrÂ±30 minutes, and 24 hrÂ±60 minutes. 
x 24-hr urine collection on Day 1 and Day 2 for PK analysis will begin immediately after study 
drug dosing on Day 1 (0-24 hr). The subject s hould void immediately before dosing and at 
the end of the 24-hr  collection period. 
x Discharge from clinic (Day 2) no less than 6 hr after the 24-hr PK sample collection 
5.3. Follow-Up Period (Day 3 to Day 29) 
5.3.1.  Follow-Up Visit (Day 8) 
The following procedures are to be performed on Day 8: 
x Limited physical examination; must incl ude a complete neur ologic examination 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 34 6 June 2022  x Weight 
x Vital signs 
x Safety laboratory tests: 
o Hematology 
o Chemistry 
o Urinalysis 
x AEs since the last visit 
x Concomitant medications and procedures since last visit 
5.3.2.  Follow-Up Visit (Day 15) 
The following procedures are to be performed on Day 15: 
x Limited physical examination; must incl ude a complete neur ologic examination 
x Vital signs 
x Safety laboratory tests: 
o Hematology 
o Chemistry 
o Urinalysis 
o Lipi[INVESTIGATOR_805] 
x AEs since the last visit 
x Concomitant medications and pr ocedures since last visit 
x Plasma PK sample 
5.3.3.  Follow-Up Visit (Day 22) 
The following procedures are to be performed on Day 22: 
x Limited physical examination; must incl ude a complete neur ologic examination 
x Vital signs 
x Safety laboratory tests: 
o Hematology 
o Chemistry 
o Urinalysis 
x AEs since the last visit 
x Concomitant medications and pr ocedures since last visit 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 35 6 June 2022  5.3.4.  Follow-Up / End of Study [EOS] Visit (Day 29) 
The following procedures are to be performed on Day 29; or if the subjec t withdraws from the study 
early, these procedures should be performed: 
x Complete physical examination; must include a complete neurologic examination 
x Weight 
x Vital signs 
x Safety laboratory tests 
o Hematology 
o Chemistry 
o Coagulation 
o Urinalysis 
o Lipi[INVESTIGATOR_805] 
x Urine pregnancy test, if applicable 
x Urine drug and alcohol screen 
x SARA Assessment 
x AEs since the last visit 
x Concomitant medications and pro cedures since the last visit 
5.4. Unscheduled Visits 
Unscheduled visits may be conducted at the Investigatorâ€™s discretion an d/or when repeat of laboratory 
assessments is needed. In addition, the following pr ocedures will occur at a ny unscheduled visits:  
x Adverse event evaluation  
x Concomitant medications and procedures  since last visit will be reviewed 
x Additional assessments may be performed, as determin ed by [CONTACT_462829]8429 
Protocol RGLS8429-[ADDRESS_592620] 
the labeled volume of 1 mL of 150 mg/mL of RG LS8429 in 0.3% saline. The solution is clear and 
colorless to pale yellow. 
6.2. Placebo 
Placebo injection will be pr ovided in [ADDRESS_592621] the 
labeled volume of 1 mL of 1.5 Î¼g/mL of riboflavin in 0.9% sodium chloride. The solution is clear and 
colorless to pale yellow. 
6.3. Storage of Study Drug 
Site staff must ensure that all study drug is stored in a secured area with cont rolled access under required 
storage conditions and in accordance with applicable  regulatory requirements. To ensure that the 
investigative staff are not unblinded, only unblinded pha rmacy staff and an unbli nded clinical research 
associate should have access to th e unblinded study drug. The clinic and non-pharmacy staff should be 
provided only with blinded syringes for injection to subjects. 
Study drug vials should be stored in  their original containers and in  accordance with the labels. Study 
drug must be stored in a freezer at  -20Â° Â± 5Â°C. The study drug should be  stored in its car ton to protect it 
from light until it is removed from the car ton to prepare for administration.  
The site must be capable of m easuring and documenting the daily minimum and maximum temperatures 
for all freezers used to store study drug. Temperatur e monitoring information s hould be captured from 
the time of study drug receipt thr oughout the duration of the study. A s ite procedure that ensures active 
evaluation for temperature excursions should be in  place and appropriate docum entation of temperature 
monitoring must be available. The minimum a nd maximum temperature should be checked each 
business day to confirm that no excursion occurred, a nd the site should have the capability to view the 
minimum/maximum temperature fo r all nonworking days upon return  to normal operations. The 
temperature monitoring device and freezer used to st ore study drug should be inspected regularly to 
ensure that they are maintained in working order.  
Any excursions from the labeled st orage conditions should be reporte d to Regulus or designee upon 
discovery. In the event of an excurs ion, the site should ensure that the product is returned to the storage 
conditions described in the labeli ng as soon as possible. Deviations  from the storag e requirements, 
including any actions taken, must be documente d, and reported to Regulus or designee.  
Receipt of study drug, opening and closing the freezer, and other routine handling operations where the 
study drug is briefly out of the temperature range described in the labeling will not be considered 
excursions.   
6.4. Subject Identification and Randomization 
The Investigator or a designee will assign sequential Screening identifi cation numbers to the subjects as 
they are screened for the study. Subjects will then be assigned different sequen tial subject identification 
numbers as they are enrolled in th e study. Details regarding subject identification procedures will be 
provided in the Study Reference Manual. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592622] 
be followed: the maximum volume for each injecti on must not exceed 2 mL (e.g., a 6-mL dose would 
require three 2 mL injections in  the abdomen). The Study Reference Manual will provide detailed 
instructions on how to prepar e and administer the study drug.  
6.7. Study Drug Accountability 
The site must maintain adequate  records documenting the receipt, preparation, use, loss, or other 
disposition of the study drug. All study drug w ill be accounted for using a drug accountability 
form/record.  
6.8. Destruction of Study Drug Supplies 
Regulus or designee will provide guidance on the destruc tion of unused study drug at the site. The 
Investigator must ensure that the materials are dest royed in compliance with applicable environmental 
regulations, institutional policy, and any special  instructions provided by [CONTACT_462830]. All study drug 
destruction must be documented adequately. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592623]â€™s 
participation in this study. A conc omitant procedure is any therapeu tic intervention (e.g., surgery/biopsy, 
physical therapy) or diagnostic as sessment (e.g., blood gas measurement, bacteria l cultures) performed 
during the subjectâ€™s partic ipation in this study.  
Concomitant medications (and dosing adjustments) a nd procedures to treat new or existing medical 
conditions or AEs will be permitted. 
All medications and procedures used in the 3 months before Randomiza tion and the subsequent 
concomitant medications and procedures received/ performed during the study must be recorded.  
7.2. Prohibited Concomitant Medications and Procedures 
Not applicable as long as guide lines for permitted concomitant medications and procedures are 
followed. 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 39 6 June 2022  8. DATA ANALYSIS / STATISTICAL METHODS 
8.1. General Considerations 
The primary objective of this study is to assess the safety and tolerability  of RGLS8429. Secondary 
objectives include characterizing th e PK of RGLS8429 and to characteri ze several exploratory urine and 
serum biomarkers.  
Tabular summaries and analysis results will be generated by [CONTACT_462831]8429 and placebo 
(pooled across all cohorts). Descri ptive statistics by [CONTACT_462832]. For continuous endpoints, the descriptive statistics will include  the number of observations, mean, 
median, standard deviation, coeffi cient of variation (%CV), first and third quartiles, minimum and 
maximum. Geometric mean and geom etric %CV will be presented where appropriate. For categorical 
endpoints, the number and percentage  of subjects will be summarized by [CONTACT_462821]. 
Details of all statistic al methods will be provided in  the Statistical Analysis Plan. 
8.2. Sample Size Determination 
Formal sample size calculations were not performe d for this study. The dose cohort size is 8 subjects 
randomized 3:[ADDRESS_592624] one Screening and/or pre-dose 
value for the biomarker parameters.  
8.4. Final Analysis 
The final analysis of th e study will be performed when all subj ects have received study drug and been 
followed for 4 weeks.  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 40 6 June 2022  8.4.1.  Disposition 
The number and percent of subjec ts enrolled, receiving assigned treatment, completed assigned 
treatment, and completing study will be tabulated by [CONTACT_14338].  Subjects who withdraw from 
study drug and/or study premat urely will be summarized by [CONTACT_462833].  
8.4.2.  Demographic and Baseline Characteristics 
Subject demographics (age, sex, race, ethnicity) and baseline characteristics will be summarized 
descriptively by [CONTACT_462834]. 
8.4.3.  Safety Analysis 
The Safety Population will be used fo r all safety analyses. No formal statistical tests will be conducted 
to assess the safety or tolerability of RGLS8429.  
Subject incidence of all TEAEs, a ll TEAEs related to study drug, and all SAEs will be tabulated by 
[CONTACT_207284]. All fatal adverse events, SAEs, and TEAEs leading to withdrawal 
from study drug will also be listed. 
The incidence of DLTs will be summar ized by [CONTACT_462821]. 
The analyses of safety laboratory tests, vital signs,  and ECGs will include summa ry statistics over time 
tabulated by [CONTACT_9084]. Similarly, changes from base line will be summarized. Shifts based on normal 
ranges between the baseline and the worst on-study value will be tabulated by [CONTACT_462835]. 
The results from the central reader assessment of EC Gs extracted from the Holter data will be used in all 
statistical analysis. The following intervals will be summarized by [CONTACT_1570]: PR, QRS, RR, HR, 
uncorrected QT, QTcB, and QTcF. Details of additio nal analyses will be provided in the Statistical 
Analysis Plan. 
The total dose of study drug and the proportion of s ubjects receiving each dose le vel will be summarized 
using descriptive statistics. 
Changes from baseline in the SARA test scores will be summarized descriptively over time and by 
[CONTACT_462836]. The SARA is a tool for assessing ataxia. It has 
eight categories with accumulative score ranging from 0 (no ataxia) to 40 (most se vere ataxia). When 
completing the outcome measure, each  category is assessed and scored accordingly. Scores for the eight 
items range as follows:  
1. Gait (0-8 points),  
2. Stance (0-6 points),  
3. Sitting (0-4 points),  
4. Speech disturbance (0-6 points),  
5. Finger chase (0-4 points),  
6. Nose-finger test (0-4 points),  
7. Fast alternating hand mo vement (0-4 points),  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 41 6 June 2022  8. Heel-shin slide (0-4 points).  
Once each of the 8 categories has been assessed, the total is calculated to de termine the severity of 
ataxia. 
For motor activities of the four ex tremities (Items 5-8), assessments are performed bilaterally, and the 
mean values are used to obtain the total score. 
8.4.4.  Pharmacokinetic Analysis 
PK samples will be analyzed using a validated, sensit ive, specific method. The laboratory analyzing the 
PK samples will be unblinded to ensure that PK analysis is performed only on subjects receiving 
RGLS8429. Placebo samples will be analyzed if necessary. Descri ptive statistics for plasma 
concentrations by [CONTACT_462837]. Descriptiv e statistics for PK parameters 
will be summarized by [CONTACT_9084].  
Concentration data will be  presented and summarized for the PK Full population. 
Using non-compartmental methods, the plasma and urine concentration data will be used to derive the 
following PK parameters: C max, Tmax, AUC 0-24, AUC 0-t, AUC inf (where calculable), t Â½, CL/F, V z/F, fe, 
and Ae. Additional PK parameters may be calculate d as appropriate. The PK Evaluable Population will 
be used for these analyses. 
Dose proportionality will be explor ed using the power model for C max, AUC 0-24, AUC 0-t, and AUC inf as 
data permit. 
8.4.5.  Biomarker Analysis 
Descriptive statistics will be  used to characterize urine (e .g., PC1, PC2, NGAL, KIM-1, MCP-1, B2M, 
and CLU) and serum (e.g., Cysta tin-C, IGFALS, Alb, CT-proAVP, N- acetyl-1-methylhistidine, and 
others) biomarkers in all subjects. The analysis of urine and se rum biomarkers is exploratory. The PD 
Population will be used for these analyses. 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 42 6 June 2022  9. ADVERSE EVENTS 
9.1. Monitoring, Recording and Reporting of Adverse Events 
An adverse event (AE) is any noxiou s, unintended, or untoward medical occurrence that may appear or 
worsen in a subject during a study. It may be a new inte rcurrent illness, a worsening concomitant illness, 
an injury, or any concomitant impai rment of the subjectâ€™s health, incl uding laboratory test values (as 
specified by [CONTACT_14540] 9.3 ), regardless of etiology. Any worsening (i.e., any clinically 
significant adverse change in  the frequency or intensity of a pre-ex isting condition) should be considered 
an AE. A diagnosis or syndrome sh ould be recorded on the AE page  of the CRF rather than the 
individual signs or symptoms of  the diagnosis or syndrome.  
Overdose (accidental or intentional), abuse, withdrawal, sensitivity, or to xicity to a study drug should be 
reported as an AE. If an overdose is associated with  an AE, the overdose and AE should be reported as 
separate terms. Any sequelae of an accidental or intentional over dose of a study drug should be reported 
as an AE on the AE CRF. If the sequelae of an over dose are a SAE, then the sequelae must be reported 
on the AE CRF and marked as serious. The overdose resulting in the SAE shoul d be identified as the 
cause of the event on the CRF but should not be reported as an SAE itself.  
In the event of overdose, the subj ect should be monitored as appropr iate and should re ceive supportive 
measures, as necessary. There is no known specific antidote for RGLS84 29 overdose. Actual treatment 
should depend on the severity of th e clinical situation a nd the judgment and expe rience of the treating 
physician. (Please refer to the RGLS8429 Investigatorâ€™s  Brochure, Summary of Data and Guidance for 
the Investigator for additional information.)  
All subjects will be monitored for AEs during the study. Assessments may include monitoring of any or 
all the following parameters: the subjectâ€™s clinical symptoms, laboratory, pathological, radiological, or 
surgical findings, physical examin ation findings, or find ings from other test s and/or procedures. 
All AEs and SAEs will be recorded by [CONTACT_462838]. All SAEs made known to the Investigator at any time thereafter that  are suspected of being 
related to study drug will also be recorded. AEs and SAEs will be recorded on the AE page of the CRF 
and in the subjectâ€™s source documents.  
9.2. Evaluation of Adverse Events 
A qualified Investigator must ev aluate all adverse events.  
9.2.1.  Seriousness  
An SAE is any AE occurring at any dose that: 
x Results in death. 
x Is life-threatening (i.e., in the opi[INVESTIGATOR_176252], the subject is at immediate risk of 
death from the AE). 
x Requires inpatient hospi[INVESTIGATOR_37511] (hospi[INVESTIGATOR_324496], regardless of length of stay). 
x Results in persistent or significant disability /incapacity (a substantial disruption of the 
subjectâ€™s ability to condu ct normal life functions). 
x Results in a congenital anomaly/birth defect. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592625] or require medical or surgical intervention to prevent one 
of the other outcomes listed above. Medical a nd scientific judgment should be exercised in 
deciding whether such an AE should be considered serious. 
Events not considered  to be SAEs are hospi[INVESTIGATOR_5315]: 
x A standard procedure for protocol therapy administration. However, hospi[INVESTIGATOR_57893] a comp lication of therapy administration will be reported as an 
SAE.  
x Routine treatment or monitoring of the st udied indication not associated with any 
deterioration in condition. 
x The administration of blood or platelet transf usion as routin e treatment of a concurrent 
medical condition. However, hospi[INVESTIGATOR_462809] a complication 
of such transfusion remains a reportable SAE. 
x A procedure for protocol/disease-related i nvestigations (e.g., surg ery, scans, endoscopy, 
sampling for laboratory tests, bone marrow sampling). However,  hospi[INVESTIGATOR_72613] a complication of such  procedures remains a reportable SAE. 
x Hospi[INVESTIGATOR_462810], pr actical, or social reasons, in 
absence of an AE. 
x A procedure that is planned (i .e., planned prior to start of  treatment on study); must be 
documented in the source document and the CRF. Hospi[INVESTIGATOR_72613] a complication remains a reportable SAE. 
x An elective treatment of or an elective procedure for a pre-existing condition, unrelated to the 
studied indication that has not  worsened from baseline.  
x Emergency outpatient treatment or observati on that does not result in admission, unless 
fulfilling other seriousness criteria above. 
If an AE is considered serious, the AE page/screen of the CRF mu st be completed and marked as 
serious. 
For each SAE, the Investigator will provide informati on on severity, start, and stop dates, relationship to 
the study drug, action taken regard ing the study drug, and outcome. 
9.2.2.  Severity/Intensity 
For both AEs and SAEs, the Investigator must as sess the severity/intensity of the event.  
The Investigator will assess the grade of the AE acco rding to the FDAâ€™s Guidance for Industry: Toxicity 
Grading Scale for Healthy Adult a nd Adolescent Volunteers Enrolled in  Preventive Vaccine Clinical 
Trials (September 2007) except for AEs associated  with abnormal serum creatinine level. The 
Investigator will use the KDIGO Clinical Pr actice Guideline for Acute Kidney Injury 
(https://kdigo.org/wp-content/upl oads/2016/10/KDIGO-2012-AKI-Guidelin e-English.pdf) to grade the 
severity of an AE associated with  abnormal serum creatinine level. Toxicities that are not specified in 
these guidances will be defined as follows:  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 44 6 June 2022  x Grade 1: Mild; asymptomatic or mild symptoms ; clinical or diagnosti c observations only; 
intervention not indicated 
x Grade 2: Moderate; minimal, local, or noninva sive intervention i ndicated; limiting age-
appropriate instrumental activities of daily living (ADL) 
x Grade 3: Severe or medically significant but not immediately life-threatening; hospi[INVESTIGATOR_462811]; disabling; limit ing self-care ADL 
x Grade 4: Life-threatening consequen ces; urgent intervention indicated 
x Grade 5: Death related to AE 
The term â€œsevereâ€ is often used to describe the inte nsity of a specific event (as in mild, moderate, or 
severe myocardial infarcti on); however, the event itself may be of relatively minor medical significance 
(such as severe headache). This criterion is not the same as â€œseriousâ€, wh ich is based on subject/event 
outcome or action criteria associated with events that pose a threat to a subjectâ€™s life or functioning. 
Seriousness, not severity, serves as a guide for defining regulatory obligations. 
9.2.3.  Causality 
The Investigator must determin e the relationship between the st udy drug and the occurrence of an 
AE/SAE. This relationship is indicated by [INVESTIGATOR_17174] â€œunrelat edâ€ or â€œrelatedâ€ in res ponse to the question: Is 
there a reasonable possibility that  the event may be caused by [CONTACT_59279]. In addition to a temporal 
relationship, the Investigator shou ld consider the following when de termining the relationship between 
an AE and study drug: whether an alternative etiol ogy has been identified, m echanism of action of the 
study drug, and/or the biological pl ausibility of a relationship. 
9.2.4.  Duration 
For both AEs and SAEs, the Investigator will provide a r ecord of the start and stop dates of the event. In 
all cases, the AE must have the same verbatim term thr oughout. Within the durati on of the SAE or AE, 
the maximum grade should be used to categorize severity. 
9.2.5.  Action Taken 
The Investigator will report the actio n taken with study drug as a result of  an AE or SAE, as applicable 
and report if concomitant and/or additiona l treatments were given for the event.  
9.2.6.  Outcome 
Subjects will be followed until AEs have either resolv ed, returned to baseline status, or are deemed 
stable or commensurate with ongoi ng disease processes, per th e Investigatorâ€™s judgment.  
One of the four outcomes liste d below must be  recorded:  
x Resolved  â€“ The subject has recove red fully from the event with no residual effects 
observable or returned to baseline status.  
x Resolved with sequelae  â€“ The subject has recovered fro m the event with some residual 
effect(s) observable. The residual effect (s) will be recorded in the CRF.  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 45 6 June 2022  x Ongoing  â€“ Effects of the event are still present, re gardless of whether th e effect is changing 
or stable and persistent.  
x Fatal outcome (for serious adverse events only)  
9.3. Abnormal Laboratory Values 
An abnormal laboratory value is an AE if the abnormality: 
x Results in discontin uation from the study. 
x Requires treatment, stoppi[INVESTIGATOR_462812], or any othe r therapeutic intervention. 
x Is judged to be clinic ally significant, e.g., one that indi cates a new disease process and/or 
organ toxicity; or is an exacerbation or worsening of an existing condition. 
Regardless of severity grade, only la boratory abnormalities that fulfill a seriousness criterion need to be 
documented as a serious adverse event. 
If a laboratory abnormality is one component of a diagnosis  or syndrome, then only the diagnosis or 
syndrome should be recorded on the AE page/screen of the CRF. If the abnormality was not a part of a 
diagnosis or syndrome, then the la boratory abnormality should be r ecorded as the AE. If possible, the 
laboratory abnormality should be record ed as a medical term and not s imply as an abnormal laboratory 
result (e.g., record thrombocytopenia rather than decreased platelets) . 
9.4. Pregnancy 
All pregnancies or suspected pregna ncies occurring in either a female  subject or female partner of a 
male subject are immedi ately reportable events .  
In the event that a pregnancy or susp HFWHGSUHJQDQF\LQFOXGLQJHOHYDWHGÈ•K&*RUSRVLWLYHSUHJQDQF\
test in a female subject) should o ccur while the subject is in study, or  within [ADDRESS_592626]â€™s 
dose of study drug, it will be considered an immedi ately reportable event. The pregnancy, suspected 
pregnancy, or positive pregnancy test must be reported to the st udy pharmacovigilance group 
immediately by [CONTACT_462839] e Pregnancy Reporting Form. 
The female subject may be referred  to an obstetrician-gynecologist or  another appropriate healthcare 
professional for further evaluation. 
The Investigator will follow the female subject un til completion of the pregnancy and must notify the 
study pharmacovigilance group immediately about the ou tcome of the pregnancy (normal or abnormal 
outcome) using the Pregnancy Follow-up Report Form. 
If the outcome of the pregnancy wa s abnormal (e.g., spontaneous aborti on), the Investigator should 
report the abnormal outcome as an AE. If the abnormal outcome meets any of the seri ous criteria, it 
must be reported as an SAE to  the study pharmacovigilance group with in 24 hr of the Investigatorâ€™s 
knowledge of the event. 
All neonatal deaths that occur within  [ADDRESS_592627] to causality, as 
SAEs. In addition, any infant death af ter 28 days that the Inve stigator suspects is re lated to the in-utero 
exposure to the study drug should also be reported to  the study pharmacovigilanc e group within 24 hr of 
the Investigatorâ€™s know ledge of the event. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592628]  be reported to the study pharmac ovigilance group within 24 hr of 
knowledge of the event.  
The Investigator is required to ensure that the da ta on these forms is accura te and consistent. This 
requirement applies to all SAEs (regardless of relationship to study drug) that occur during the study 
(from the administration of study drug until the EOS Vi sit) or any SAE made known to the Investigator 
at any time thereafter that are susp ected of being related to study drug.  
The SAE report should provide a detailed descripti on of the SAE and include  a concise summary of 
hospi[INVESTIGATOR_27598]. If a subj ect died and an autopsy has been performed, copi[INVESTIGATOR_462813]. Any follow-up data should  be detailed in the AE CRF.  
Where required by [CONTACT_19666], the Investigator  is responsible for informing the Institutional 
Review Board/Ethics Committee (IRB/EC) of the SAE and providing them with a ll relevant initial and 
follow-up information about th e event. The Investigator must keep copi[INVESTIGATOR_462814] w ith the study pharmacovigila nce group and the IRB/EC. 
9.6. Safety Queries 
Queries pertaining to SAEs will be communicated from the study pharm acovigilance group to the site 
via electronic mail. The response time is expected to  be no more than five (5) business days. Urgent 
queries (e.g., missing causality asse ssment) may be handled by [CONTACT_648]. 
9.7. Expedited Reporting of Adverse Events 
For the purpose of regulatory reporting, the Sponsorâ€™s  Lead Physician will determine the expectedness 
of events suspected of being re lated to study drug based on info rmation in the Reference Safety 
Information section of the Investigator Brochure.  
All suspected unexpected serious adverse reactions (S [LOCATION_003]Rs) will be reported in an expedited manner 
in accordance local and FDA (21 CFR 312.32) regulations. 
The study pharmacovigilance group shall notify the Investigator of the following information: 
x Any AE suspected of being related to the use of study drug in this st udy or in other studies 
that is both serious and unexpected (i.e., S[LOCATION_003]R). 
x Any finding from tests in laborat ory animals that suggests a significant risk for human 
subjects including reports of mutagenici ty, teratogenicity, or carcinogenicity. 
Where required by [CONTACT_19666], th e Investigator shall notify his/he r IRB/EC promptly of these new 
serious and unexpected AE(s) or significant risks to subjects. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592629] keep copi[INVESTIGATOR_462815]/EC. (See Section 13.[ADDRESS_592630] retention information). 
9.8. Study Pharmacovigilance Group Contact [CONTACT_462840]8429 
Protocol RGLS8429-[ADDRESS_592631] from the study drug and/or 
from the study: 
x Protocol violation 
x Non-compliance 
x Adverse event 
x Withdrawal by [CONTACT_1130] 
x Subject lost to follow-up 
x Sponsor decision 
x Investigator decision 
x Pregnancy or pre gnancy of partner 
x Death 
x Other  
The reason for discontinuation shou ld be recorded in the CRF and in the source documents. 
The decision to discontinue a subject remains the responsibility of the treating physician, which will not 
be delayed or refused by [CONTACT_1034]. However, prio r to discontinuing a subject , the Investigator should 
(if possible) contact [CONTACT_1034]â€™s  Lead Physician and forward appr opriate supporting documents (if 
possible) for review  and discussion. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592632] the Sponsorâ€™s Lead Physician or design ee by [CONTACT_462841] r(s) listed in the Study 
Reference Manual. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592633], evaluati on, and documentation of 
this study are designed to ensure th at the Sponsor, its authorized repr esentative, and Investigator abide 
by [CONTACT_23663] (GCP), as described in  International Conferen ce on Harmonisation (ICH) 
Guideline E6 (R2) and in accordance with the genera l ethical principles outlined  in the Declaration of 
Helsinki. The study will receive a pproval from an IRB/EC prior to commencement. The Investigator 
will conduct all aspects of this study in accordance with applicable national, state, and local laws of the 
pertinent regulatory authorities. 
12.2. Investigator Responsibilities 
Investigator responsibilitie s are set out in the ICH Guideline for Good Clinical Practice E6 (R2) and in 
the local regulations. Regulus staff or an authoriz ed representative will evaluate and approve all 
Investigators who in turn will select their staff. 
The Investigator should ensure th at all persons assisti ng with the study are adequately informed about 
the protocol, amendments, study trea tments, as well as study-related  duties and functions, including 
obligations of confidentiality of Regulus information. The Investigator should ma intain a list of Sub-
Investigators and other a ppropriately qualified persons to whom he or she has delegated significant 
study-related duties. 
The Investigator is responsible for keepi[INVESTIGATOR_007] a record of all subjects w ho sign an informed consent form 
(ICF) and are screened for entry into the study. Subjects who fail Sc reening must have the reason(s) 
recorded in the subjectâ€™s source documents. 
The Investigator, or a designated member of the Investigatorâ€™s st aff, must be available during 
monitoring visits to review data, resolve queries a nd allow direct access to su bject records (e.g., medical 
records, office charts, hospi[INVESTIGATOR_1332], and study -related charts) for sour ce data verification. The 
Investigator must ensure timely and accu rate completion of CRFs and queries. 
The information contained in the protocol and amendments (excep t for the information provided by 
[CONTACT_462842])  is considered Regulus confiden tial information. Only information 
that is disclosed previously by [CONTACT_462843] a public  registry website may be  freely disclosed by [CONTACT_462844], or as outlined in th e Clinical Trial Agreement. The Regulus protocol, 
amendments, and IB information are not to be made publicly available (for example on the 
Investigatorâ€™s or their institutionâ€™s website) withou t express written approval from Regulus. Information 
proposed for posting on the Investigato râ€™s or their institutionâ€™s website must be submitted to Regulus for 
review and approval, providing at least [ADDRESS_592634] and/ or their caregiver as agreed by [CONTACT_423]. 
12.3. Subject Information and Informed Consent 
The Investigator must obtain inform ed consent of a subject and/or a subjectâ€™s legal representative prior 
to any study-related procedures. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592635]â€™s entry into the study and of 
the informed consent process shoul d be recorded in the study subj ectâ€™s source documen ts including the 
date. The original ICF signed and dated by [CONTACT_462845]â€™ s entry into the study, must be main tained in the Investigatorâ€™s study 
files and a copy given to the study subject. In additi on, if a protocol is amended and it impacts on the 
content of the informed consent, the ICF must be re vised. Study subjects partic ipating in the study when 
the amended protocol is implemented must be re-consented with the revised version of the ICF. The 
revised ICF signed and dated by [CONTACT_3433] e study subject and by [CONTACT_108443] c onsenting the study subject must 
be maintained in the Inves tigatorâ€™s study files and a copy given to the study subject. 
12.4. Confidentiality 
Regulus affirms the subject's right to protection against invasion of pr ivacy and to follow ICH and other 
local regulations (whichever is mo st stringent). Regulus requires the Investigat or to permit Regulus 
representatives and, when necessary, representatives fr om regulatory authorities, to review and/or copy 
any medical records relevant to the study in accordance with local laws. 
Should direct access to medical records require a waiv er or authorization separate from the subjectâ€™s 
signed ICF, it is the responsibility of the Investigator to obtain su ch permission in writing from the 
appropriate individual. 
12.5. Protocol Amendments 
Any amendment to this protocol must be approved by [CONTACT_462846]/EC for 
written approval. Written approval must be obtained before implem entation of the amended version 
occurs. The written signed approva l from the IRB/EC should specifica lly reference the Investigator 
name, protocol number, study title, and amendment number(s) that are applicable. Amendments that are 
administrative in nature do not require IRB/IEC a pproval but will be submitted to the IRB/IEC for 
information purposes. 
12.6. Institutional Review Board/Independent Ethics Committee Review and Approval 
Before the start of the study, the study protocol, ICF, and any othe r appropriate documents will be 
submitted to the IRB/EC with a cover letter or a fo rm listing the documents s ubmitted, thei r dates of 
issue, and the site (or region or  area of jurisdiction, as applicab le) for which approval is sought. If 
applicable, the documents will also be submitted to  the authorities in accordance with local legal 
requirements. 
RGLS8429 can be supplied to an Investigator by [CONTACT_462847] l requirements for starting the study has been received by [CONTACT_462848]. This documentation must also include  a list of the members of the 
IRB/EC and their occupation and qualifications. If th e IRB/EC will not disclose the names, occupations, 
and qualifications of the committee me mbers, it should be asked to issu e a statement confirming that the 
composition of the committee is in accordance with  GCP. For example, the IRB General Assurance 
Number may be accepted as a substitute for this list.  Formal approval by [CONTACT_941] I RB/EC should mention the 
protocol title, number, am endment number (if applicab le), study site (or region or  area of jurisdiction, as 
applicable), and any other documen ts reviewed. It must mention th e date on which the decision was 
made and must be officially signed by a committee me mber. Before the first subject is enrolled in the 
study, all ethical and legal re quirements must be met. 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 52 6 June 2022  The IRB/EC and, if applicable, the au thorities, must be info rmed of all subsequent protocol amendments 
in accordance with local legal re quirements. Amendments must be evaluated to determine whether 
formal approval must be sought and wh ether the ICF should also be revised. 
The Investigator must keep a reco rd of all communication with the I RB/EC and, if applicable, between a 
Coordinating Investigator [INVESTIGATOR_55532] e IRB/EC. This statement also ap plies to any communication between 
the Investigator (or C oordinating Investigator, if applicable) and re gulatory authorities. 
Any advertisements used to recrui t subjects for the study must be re viewed by [CONTACT_462849]/EC 
prior to use.  
12.7. Ongoing Information for Institutiona l Review Board/ Ethics Committee 
If required by [CONTACT_27735]/EC, th e Investigator must submit to the IRB/EC: 
x Information on serious or unexpected a dverse events as soon as possible  
x Periodic reports on the progress of the study 
x Deviations from the protocol or anything th at may involve added risk to subjects in 
accordance with IRB/EC guidelines 
12.8. Termination of the Study 
Regulus reserves the right to terminate this study at  any time for reasonable medical or administrative 
reasons. Any premature discontinuation will be documented appropriately according to local 
requirements (e.g., IRB/EC, regul atory authorities, etc.). 
In addition, the Investigator or Regu lus has the right to discontinue a single site at any time during the 
study for medical or admini strative reasons such as: 
x Unsatisfactory enrollment 
x GCP noncompliance 
x Inaccurate or incomplete data collection 
x Falsification of records 
x Failure to adhere to the study protocol 
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 53 6 June 2022  13. DATA HANDLING AN D RECORDKEEPI[INVESTIGATOR_1645]  
13.1. Data/Documents 
The Investigator must ensure that  the records and documen ts pertaining to the c onduct of the study and 
the distribution of the study drug are complete, accurate, filed, a nd retained. Examples of source 
documents include hospi[INVESTIGATOR_1097];  clinic and office charts; labora tory notes; memoranda; subjectâ€™s 
diaries or evaluation checklists; disp ensing records; recorded data from automated instruments; copi[INVESTIGATOR_462816]; mic rofiche; x-ray film and reports; 
and records kept at the pharmacy, and the la boratories, as well as copi[INVESTIGATOR_3110]. 
13.2. Data Management 
Data will be collected via CRF, and data entry will be performed through username- and password-
protected access to a secure database. These data  will be verified electr onically through use of 
programmed edit checks specified by [CONTACT_1034]. Disc repancies in the data will be brought to the 
attention of the Sponsor and investigational site person nel, as necessary. Resoluti ons to these issues will 
be reflected in the database. An audit trail within the system will track all changes made to the data. 
13.3. Record Retention 
Essential documents must be retained by [CONTACT_462850]. The Investigator must retain thes e documents for the time period described above or 
according to local laws or requirements, whichever is longer. Essential docu ments include, but are not 
limited to, the following: 
x Signed ICFs for all subjects 
x Subject identification code list, Screening log (if applicable), and enrollment log 
x Record of all communications betwee n the Investigator and the IRB/EC 
x Composition of the IRB/EC 
x Record of all communications between the In vestigator, Regulus, and their authorized 
representative(s) 
x List of Sub-Investigators and ot her appropriately quali fied persons to whom the Investigator 
has delegated significant study-related duties,  together with thei r roles in the study, 
curriculum vitae, and their signatures 
x RGLS8429 accountability records 
x Record of any body fluids or  tissue samples retained 
x All other source documents (subject records,  hospi[INVESTIGATOR_1097], labor atory records, etc.) 
x All other documents as listed  in Section 8 of the ICH c onsolidated guideline on GCP 
(Essential Documents for the C onduct of a Clinical Trial) 
The Investigator must notif y Regulus if he/she wishes to assign the essential documents to someone else, 
remove them to another location, or  is unable to retain them for a specified period. Th e Investigator 
must obtain approval in writing from Re gulus prior to destruction of any records. If the Investigator is 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592636] to current GCP and SOPs. 
14.1. Study Monitoring and Source Data Verification 
Regulus or designee ensures that appropriate monitoring procedures are performed before, during, and 
after the study. All as pects of the study are reviewed with th e Investigator and the staff at a study 
initiation visit and/or at an Invest igatorsâ€™ Meeting. Prior to enroll ing subjects into the study, a Regulus 
representative or designee will review the protocol , CRFs, procedures for obtaining informed consent, 
record keepi[INVESTIGATOR_007], and reporting of AEs/SAEs with the Investigator. Monitoring w ill include on-site visits 
with the Investigator and his/her staff as well as any appropria te communications by [CONTACT_2319], email, or 
telephone. During monitoring visits , the facilities, study drug storag e area, CRFs, subjectâ€™s source 
documents, and all other study documentation will be inspected/reviewed by [CONTACT_462851]. 
Accuracy will be checked by [CONTACT_462852] a direct comparison of the 
entries made onto the CRFs against the appropriate source documenta tion. Any resulting discrepancies 
will be reviewed with the Investigator and/or his/ her staff. Any necessary corrections will be made 
directly to the CRFs or via queries  by [CONTACT_11219]/or his/ her staff. Monitoring procedures 
require that informed consents, adherence to incl usion/exclusion criteria, and documentation of SAEs 
and their proper recording be ve rified. Additional monitoring activit ies may be outlined in a study-
specific monitoring plan. 
14.2. Audits and Inspections 
In addition to the routine monitori ng procedures, a representative of  Regulus or designee may conduct 
audits of clinical research activ ities to evaluate compliance with Good Clinical Practice guidelines and 
regulations. 
The Investigator is required to pe rmit direct access to th e facilities where the st udy took place, source 
documents, CRFs, and applicable supporting records of study subject partic ipation for audits and 
inspections by [CONTACT_1744]/ECs, regulator y authorities, and company-aut horized representatives. The 
Investigator should make every effort  to be available for th e audits and/or inspecti ons. If the Investigator 
is contact[CONTACT_462853], he /she should contact [CONTACT_462854]. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592637] authorship, will be based on several 
considerations, includ ing, but not limited to, cont ribution to protocol devel opment, study recruitment, 
data quality, participation in data analysis, particip ation in study steering committee (when applicable), 
and contribution to abstract, presenta tion, and/or publication development. 
RGLS8429 
Protocol RGLS8429-[ADDRESS_592638] O, Eckardt DU, et al. Autosomal-dominant polyc ystic kidney disease 
(ADPKD): executive summary from a Kidney Dise ase: Improving Globa l Outcomes (KDIGO) 
Controversies Conference. Kidney Int . 2015;88(1):17-27. 
Chebib FT, Torres VE. Autosomal Dominant Polycy stic Kidney Disease: Core Curriculum 2016. 
Am J Kidney Dis . 2016;67(5):792-810.  
Dong K, Zhang, C, Tian X, Coman, D, Hyder F, Ma M, Somlo, S. Renal plasticity revealed through 
reversal of polycystic kidney disease in mice. Nature Genetics . 2021;1-15. 10.1038/s41588-021-
[ZIP_CODE]-4. 
Hajarnis S, Lakhia R, Yheskel M, Williams D, So rourian M, Liu X, Aboudehen K, Zhang S, Kersjes 
K, Galasso R, Li J, Kaimal V, Lockton S, Davi s S, Flaten A, Johnson JA, Holland WL, Kusminski 
CM, Scherer PE, Harris PC, Trudel M, Wallace DP, Ig arashi P, Lee EC, Androsavich JR, Patel V. 
microRNA-17 family promotes polycystic kidney disease pr ogression through modulation of 
mitochondrial metabolism. Nat Commun . 2017 Feb 16;8:[ZIP_CODE]. 
Hogan MC, Bakeberg JL, Gainullin VG, Irazabal MV, Harmon AJ, Lieske JC, Charlesworth MC, 
Johnson KL, Madden BJ, Zenka RM, McCormick DJ , Sundsbak JL, Heyer CM, Torres VE, Harris 
PC, Ward CJ. Identification of Biomarke rs for PKD1 Using Urinary Exosomes. J Am Soc Nephrol . 
2015 Jul;26(7):1661-70.  
Inker LA, Eneanya ND, Coresh J, et al. New creatin ine- and cystatin Câ€“base d equations to estimate 
GFR without race. N Engl J Med  2021;385:1737-49. DOI: 10.1056/NEJMoa2102953 
Lee E,Valencia T, Allerson C, Schairer A, Flaten A, Yheskel, M, Kersjes K, Li J, Gatto, S, Takhar 
M, Lockton S, Pavlicek A, Kim M, Chu T, Soria no R, Davis S, Androsavich J, Sarwary S, Owen T, 
Patel V. Discovery and preclinical evaluation of anti-miR-17 oligonuc leotide RGLS4326 for the 
treatment of polycys tic kidney disease. Nature Communications.  2019;10. 1-14. 10. 
Lee E, Valencia TM, Owen T, Neben S, Cremer KF, Garg R, Drygin D, Ward CJ, Yu ASL, Patel V. 
RGLS4326 Increases Urinary PC1 and PC2 Levels  in Individuals with Autosomal Dominant 
Polycystic Kidney Disease (ADPKD). American Society of Nephrology . Abstract PO1244. 2021 
Patel V, Williams D, Hajarnis S, Hunter R, P ontoglio M, Somlo S, Igarashi P. miR-17~[ADDRESS_592639] gr owth in polycystic kidney disease.  Proc Natl Acad Sci U S A. 2013 
Jun 25;110(26):[ZIP_CODE]-70.  
Torres VE, Harris PC. Autosomal dominant polycy stic kidney disease: the last 3 years. Kidney Int . 
2009;76:149-168. 
  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 58 6 June 2022  APPENDIX A.  TABLE OF ABBREVIATIONS 
Abbreviation  Explanation 
%CV Coefficient of variation 
ADA Anti-drug antibodies 
ADPKD Autosomal dominant polycystic kidney disease 
ADL Activities of daily living 
Ae Total amount of unchanged RG LS8429 excreted in the urine 
AE Adverse event 
Alb Albumin 
ALT Alanine aminotransferase  
AUC 0-24 Area under the concentrationâ€“t ime curve up to [ADDRESS_592640] dose 
AUC 0-t Area under the concentrationâ€“t ime curve up to the last qu antifiable concentration 
AUC inf Area under the concentrationâ€“time cu rve extrapolated to infinity 
aPTT Activated partial thromboplastin time 
AST Aspartate aminotransferase  
BMI  Body mass index  
B2M beta-2 microglobulin 
BP Blood pressure 
BUN  Blood urea nitrogen  
CKD-EPI [INVESTIGATOR_462817]/F Apparent clearance 
Cmax Maximum observed concentration 
CT-proAVP  
CK Creatine kinase 
CRF Case report form 
CRO Clinical Research Organization 
DLT Dose-limiting toxicity 
ECG  Electrocardiogram  
EOS  End of study  
fe Fraction of unchanged RGLS [ADDRESS_592641] Hematocrit 
HED Human equivalent dose 
HIV Human immunodeficiency virus 
HR Heart rate 
IGFALS Insulin-like Growth Factor Binding Protein Acid Labile Subunit  
ICF Informed consent form  
ICH  International Conf erence on Harmonisation  
INR  International normalized ratio   
IUD Intrauterine device 
IUS Intrauterine system 
KIM-1 Kidney injury molecule 1 
LDH  Lactate dehydrogenase  
MCH Mean corpuscular hemoglobin 
MCHC Mean corpuscular hemoglobin concentration 
MCP-1 monocyte chemoattra ctant protein-1 (MCP-1) 
MCV Mean corpuscular volume 
miRNA MicroRNA 
MTD Maximum tolerated dose 
ncRNA Non-coding microRNA 
mmHg Millimeters of mercury  
MRI  Magnetic resonance imaging  
NOAEL No-observed-adverse-effect Level 
NGAL Neutrophil gelatinase-associated lipocalin 
PC1 Polycystin [ADDRESS_592642]  Upper limit of normal  
Vz/F Volume of distribution 
WBC  White blood cells  
RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 61 6 June 2022  APPENDIX B.  SCALE FOR THE ASSESSMENT AND RATING OF ATAXIA 
(SARA) 
Schmitz-HÃ¼bsch T, Tezenes du Montcel S, Baliko L, et  al: Scale for the assessme nt and rating of ataxia: 
development of a new clinical scale. Neurology  66:1717-1720, 2006. 
 

RGLS8429 
Protocol RGLS8429-01 v3.0  Regulus Therapeutics Inc. 
Confidential and Proprietary 62 6 June 2022   
                        
 
                    
